1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.
Levy, R. (1999). 1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session. Biochimica Et Biophysica Acta, 1424(2-3), R43–4.

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
Davis, T. A., White, C. A., Grillo-Lopez, A. J., Velasquez, W. S., Link, B., Maloney, D. G., … Levy, R. (1999). Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab. JOURNAL OF CLINICAL ONCOLOGY, 17(6), 1851–57.

Karnofsky Lecture: Immunotherapy of lymphoma
Levy, R. (1999). Karnofsky Lecture: Immunotherapy of lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 17(11), 7–12.

Mutation analysis of the 5 ' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity
Lossos, I. S., & Levy, R. (2000). Mutation analysis of the 5 ' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. BLOOD, 95(4), 1400–1405.

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., … Staudt, L. M. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. NATURE, 403(6769), 503–11.

Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas
Lossos, I. S., Okada, C. Y., Tibshirani, R., Warnke, R., Vose, J. M., Greiner, T. C., & Levy, R. (2000). Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. BLOOD, 95(5), 1797–1803.

Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
Timmerman, J. M., & Levy, R. (2000). Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. JOURNAL OF IMMUNOLOGY, 164(9), 4797–4803.

Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma
Wong, C. P., & Levy, R. (2000). Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma. CANCER RESEARCH, 60(10), 2689–2695.

Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5 ' noncoding regulatory region of the BCL-6 gene
Lossos, I. S., & Levy, R. (2000). Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5 ' noncoding regulatory region of the BCL-6 gene. BLOOD, 96(2), 635–639.

Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas
Lossos, I. S., Alizadeh, A. A., Eisen, M. B., Chan, W. C., Brown, P. O., Botstein, D., … Levy, R. (2000). Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97(18), 10209–13.

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., … Levy, R. (2000). Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. JOURNAL OF CLINICAL ONCOLOGY, 18(17), 3135–43.

The inference of antigen selection on Ig genes
Lossos, I. S., Tibshirani, R., Narasimhan, B., & Levy, R. (2000). The inference of antigen selection on Ig genes. JOURNAL OF IMMUNOLOGY, 165(9), 5122–5126.

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma
Liso, A., Stockerl-Goldstein, K. E., Auffermann-Gretzinger, S., Benike, C. J., Reichardt, V., van Beckhoven, A., … Levy, R. (2000). Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(6), 621–627.

A perspective on monoclonal antibody therapy: Where we have been and where we are going
Levy, R. (2000). A perspective on monoclonal antibody therapy: Where we have been and where we are going. SEMINARS IN HEMATOLOGY, 37(4), 43–46.

'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns.
Hastie, T., Tibshirani, R., Eisen, M. B., Alizadeh, A., Levy, R., Staudt, L., … BROWN, P. (2000). 'Gene shaving' as a method for identifying distinct sets of genes with similar expression patterns. Genome Biology, 1(2), RESEARCH0003-?

Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas
Timmerman, J. M., Caspar, C. B., Lambert, S. L., Syrengelas, A. D., & Levy, R. (2001). Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. BLOOD, 97(5), 1370–1377.

The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes
Alizadeh, A., Eisen, M., Davis, R. E., Ma, C., Sabet, H., Tran, T., … Staudt, L. M. (1999). The lymphochip: A specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Presented at the 64th Symposia: Signaling and Gene Expression in the Immune System, NEW YORK,NY,NY,NY: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT.

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
Lossos, I. S., Jones, C. D., Warnke, R., Natkunam, Y., Kaizer, H., Zehnder, J. L., … Levy, R. (2001). Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. BLOOD, 98(4), 945–51.

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
Weng, W. K., & Levy, R. (2001). Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. BLOOD, 98(5), 1352–57.

T cell antigen receptor vaccines for active therapy of T cell malignancies
Reddy, S. A., Okada, C., Wong, C., Bahler, D., & Levy, R. (2001). T cell antigen receptor vaccines for active therapy of T cell malignancies. Presented at the Conference on Basic and Clinical Relevant Biology of Cutaneous T Cell Lymphoma, NEW YORK,NY,NY,NY,NY,NY,NY: NEW YORK ACAD SCIENCES.

Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma
Davis, T. A., Hsu, F. J., Caspar, C. B., van Beckhoven, A., Czerwinski, D. K., Liles, T. M., … Levy, R. (2001). Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(9), 517–22.

The history of the development of vaccines for the treatment of lymphoma.
Timmerman, J. M., & Levy, R. (2000). The history of the development of vaccines for the treatment of lymphoma. Clinical Lymphoma, 1(2), 129–139.

BLyS* and BLyS receptor expression in non-Hodgkin's lymphoma
Briones, J., Timmerman, J. M., Hilbert, D. M., & Levy, R. (2002). BLyS* and BLyS receptor expression in non-Hodgkin's lymphoma. EXPERIMENTAL HEMATOLOGY, 30(2), 135–41.

Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., Blume, K. G., … Shizuru, J. A. (2002). Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. BLOOD, 99(4), 1442–48.

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients
Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., … Levy, R. (2002). Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. BLOOD, 99(5), 1517–26.

A polymorphism in the BCL-6 gene is associated with follicle center lymphoma
Lossos, I. S., Jones, C. D., Zehnder, J. L., & Levy, R. (2001). A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. LEUKEMIA & LYMPHOMA, 42(6), 1343–50.

In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma
Briones, J., Timmerman, J., & Levy, R. (2002). In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. CANCER RESEARCH, 62(11), 3195–99.

Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes
Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Thorstenson, Y., Oefner, P. J., … Levy, R. (2002). Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(13), 8886–91.

Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma
Lossos, I. S., Thorstenson, Y. R., Wayne, T. L., Oefner, P. J., Levy, R., & Chu, G. (2002). Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma. LEUKEMIA & LYMPHOMA, 43(5), 1079–85.

BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5 ' regulatory region of the BCL-6 gene
Lossos, I. S., Warnke, R., & Levy, R. (2002). BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5 ' regulatory region of the BCL-6 gene. LEUKEMIA, 16(9), 1857–1862.

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma
Timmerman, J. M., Singh, G., Hermanson, G., Hobart, P., Czerwinski, D. K., Taidi, B., … Levy, R. (2002). Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. CANCER RESEARCH, 62(20), 5845–52.

Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations
Martinez-Climent, J. A., Alizadeh, A. A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D. G., … Lossos, I. S. (2003). Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. BLOOD, 101(8), 3109–17.

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma
Lossos, I. S., Alizadeh, A. A., Rajapaksa, R., Tibshirani, R., & Levy, R. (2003). HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. BLOOD, 101(2), 433–40.

Variation in gene expression patterns in follicular lymphoma and the response to rituximab
Bohen, S. P., Troyanskaya, O. G., Alter, O., Warnke, R., Botstein, D., Brown, P. O., & Levy, R. (2003). Variation in gene expression patterns in follicular lymphoma and the response to rituximab. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(4), 1926–30.

Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: Correlation with clinical outcome
Lossos, I. S., Natkunam, Y., Levy, R., & Lopez, C. D. (2002). Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: Correlation with clinical outcome. LEUKEMIA & LYMPHOMA, 43(12), 2309–17.

Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules
Briones, J., Timmerman, J. M., Panicalli, D. L., & Levy, R. (2003). Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 95(7), 548–55.

Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies
Lossos, I. S., Czerwinski, D. K., Wechser, M. A., & Levy, R. (2003). Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. LEUKEMIA, 17(4), 789–795.

Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies
Levy, R. (2003). Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. LEUKEMIA, 17(4), 796–797.

BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma
Akasaka, T., Lossos, I. S., & Levy, R. (2003). BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. BLOOD, 102(4), 1443–48.

The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene
Lossos, I. S., Akasaka, T., Martinez-Climent, J. A., Siebert, R., & Levy, R. (2003). The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene. LEUKEMIA, 17(7), 1390–1397.

Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma
Do, B., Lossos, I. S., Thorstenson, Y., Oefner, P. J., & Levy, R. (2003). Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma. LEUKEMIA & LYMPHOMA, 44(8), 1317–1323.

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
Weng, W. K., & Levy, R. (2003). Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 21(21), 3940–47.

Antigen selection in human lymphomagenesis.
Bahler, D. W., Zelenetz, A. D., Chen, T. T., & Levy, R. (1992). Antigen selection in human lymphomagenesis. Cancer Research, 52(19), 5547s–5551s.

INDUCTION OF IMMUNE-RESPONSES IN PATIENTS WITH B-CELL LYMPHOMA AGAINST THE SURFACE-IMMUNOGLOBULIN IDIOTYPE EXPRESSED BY THEIR TUMORS
Kwak, L. W., Campbell, M. J., Czerwinski, D. K., Hart, S., MILLER, R. A., & Levy, R. (1992). INDUCTION OF IMMUNE-RESPONSES IN PATIENTS WITH B-CELL LYMPHOMA AGAINST THE SURFACE-IMMUNOGLOBULIN IDIOTYPE EXPRESSED BY THEIR TUMORS. NEW ENGLAND JOURNAL OF MEDICINE, 327(17), 1209–15.

EVALUATION OF THE CELL-DYN 3000 DIFFERENTIAL
Cornbleet, P. J., Myrick, D., JUDKINS, S., & Levy, R. (1992). EVALUATION OF THE CELL-DYN 3000 DIFFERENTIAL. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 98(6), 603–614.

TCR vaccines against a murine T cell lymphoma: A primary role for antibodies of the IgG2c class in tumor protection
Lambert, S. L., Okada, C. Y., & Levy, R. (2004). TCR vaccines against a murine T cell lymphoma: A primary role for antibodies of the IgG2c class in tumor protection. JOURNAL OF IMMUNOLOGY, 172(2), 929–36.

Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas
Reddy, S. A., & Levy, R. (2004). Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 124(5), 626–28.

CLONAL EVOLUTION OF A FOLLICULAR LYMPHOMA - EVIDENCE FOR ANTIGEN SELECTION
Bahler, D. W., & Levy, R. (1992). CLONAL EVOLUTION OF A FOLLICULAR LYMPHOMA - EVIDENCE FOR ANTIGEN SELECTION. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 89(15), 6770–6774.

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
Lossos, I. S., Czerwinski, D. K., Alizadeh, A. A., Wechser, M. A., Tibshirani, R., Botstein, D., & Levy, R. (2004). Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. NEW ENGLAND JOURNAL OF MEDICINE, 350(18), 1828–37.

MONOCLONAL ANTIIDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA - THE ADDITION OF A SHORT COURSE OF CHEMOTHERAPY DOES NOT INTERFERE WITH THE ANTITUMOR EFFECT NOR PREVENT THE EMERGENCE OF IDIOTYPE-NEGATIVE VARIANT CELLS
Maloney, D. G., Brown, S., Czerwinski, D. K., Liles, T. M., Hart, S. M., MILLER, R. A., & Levy, R. (1992). MONOCLONAL ANTIIDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA - THE ADDITION OF A SHORT COURSE OF CHEMOTHERAPY DOES NOT INTERFERE WITH THE ANTITUMOR EFFECT NOR PREVENT THE EMERGENCE OF IDIOTYPE-NEGATIVE VARIANT CELLS. BLOOD, 80(6), 1502–10.

AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity
Lossos, I. S., Levy, R., & Alizadeh, A. A. (2004). AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. LEUKEMIA, 18(11), 1775–79.

USE OF FAMILY SPECIFIC LEADER REGION PRIMERS FOR PCR AMPLIFICATION OF THE HUMAN HEAVY-CHAIN VARIABLE REGION GENE REPERTOIRE
Campbell, M. J., Zelenetz, A. D., Levy, S., & Levy, R. (1992). USE OF FAMILY SPECIFIC LEADER REGION PRIMERS FOR PCR AMPLIFICATION OF THE HUMAN HEAVY-CHAIN VARIABLE REGION GENE REPERTOIRE. MOLECULAR IMMUNOLOGY, 29(2), 193–203.

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype
Weng, W. K., Czerwinski, D., Timmerman, J., Hsu, F. J., & Levy, R. (2004). Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. JOURNAL OF CLINICAL ONCOLOGY, 22(23), 4717–24.

Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system
Yang, J. H., Kanter, G., Voloshin, A., Levy, R., & Swartz, J. R. (2004). Expression of active murine granulocyte-macrophage colony-stimulating factor in an Escherichia coli cell-free system. BIOTECHNOLOGY PROGRESS, 20(6), 1689–96.

The radioisotope contributes significantly to the activity of radioimmunotherapy
Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Zelenetz, A., … Knox, S. J. (2004). The radioisotope contributes significantly to the activity of radioimmunotherapy. CLINICAL CANCER RESEARCH, 10(23), 7792–98.

Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system
Yang, J. H., Kanter, G., Voloshin, A., Michel-Reydellet, N., Velkeen, H., Levy, R., & Swartz, J. R. (2005). Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. BIOTECHNOLOGY AND BIOENGINEERING, 89(5), 503–11.

Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation
Natkunam, Y., Lossos, L. S., Taidi, B., Zhao, S. C., Lu, X. Q., Ding, F. Y., … Levy, R. (2005). Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. BLOOD, 105(10), 3979–86.

Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells
Song, W. R., & Levy, R. (2005). Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. CANCER RESEARCH, 65(13), 5958–64.

Vaccines in lymphoma.
Levy, R. (2004). Vaccines in lymphoma. Clinical Advances in Hematology & Oncology : H&O, 2(7), 424-?

TUMOR RESISTANCE INDUCED BY SYNGENEIC BONE-MARROW TRANSPLANTATION AND ENHANCED BY INTERLEUKIN-2 - A MODEL FOR THE GRAFT VERSUS LEUKEMIA REACTION
Kwak, L. W., Campbell, M. J., & Levy, R. (1992). TUMOR RESISTANCE INDUCED BY SYNGENEIC BONE-MARROW TRANSPLANTATION AND ENHANCED BY INTERLEUKIN-2 - A MODEL FOR THE GRAFT VERSUS LEUKEMIA REACTION. CANCER RESEARCH, 52(15), 4117–4120.

Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma
Guardino, A. E., Rajapaksa, R., Ong, K. H., Sheehan, K., & Levy, R. (2006). Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma. CYTOTHERAPY, 8(3), 277–289.

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells
Irish, J. M., Czerwinski, D. K., Nolan, G. P., & Levy, R. (2006). Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma. B cells from tumor-infiltrating nonmalignant B cells. BLOOD, 108(9), 3135–42.

Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry
Irish, J. M., Czerwinski, D. K., Nolan, G. P., & Levy, R. (2006). Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. JOURNAL OF IMMUNOLOGY, 177(3), 1581–89.

Therapy of lymphoma directed at idiotypes.
Levy, R., & MILLER, R. A. (1990). Therapy of lymphoma directed at idiotypes. Journal of the National Cancer Institute. Monographs, (10), 61–68.

TAPA-1, THE TARGET OF AN ANTIPROLIFERATIVE ANTIBODY, DEFINES A NEW FAMILY OF TRANSMEMBRANE PROTEINS
Oren, R., Takahashi, S., Doss, C., Levy, R., & Levy, S. (1990). TAPA-1, THE TARGET OF AN ANTIPROLIFERATIVE ANTIBODY, DEFINES A NEW FAMILY OF TRANSMEMBRANE PROTEINS. MOLECULAR AND CELLULAR BIOLOGY, 10(8), 4007–4015.

Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival
Natkunam, Y., Hsi, E. D., Aoun, P., Zhao, S., Elson, P., Pohlman, B., … Lossos, I. S. (2007). Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. BLOOD, 109(1), 298–305.

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphorna patients regardless of their response to induction chemotherapy
Weng, W.-K., Czerwinski, D., & Levy, R. (2007). Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphorna patients regardless of their response to induction chemotherapy. BLOOD, 109(3), 951–53.

The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas
Natkunam, Y., Zhao, S., Mason, D. Y., Chen, J., Taidi, B., Jones, M., … Levy, R. (2007). The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. BLOOD, 109(4), 1636–42.

AN EPITOPE ON THE TRANSFERRIN RECEPTOR PREFERENTIALLY EXPOSED DURING TUMOR PROGRESSION IN HUMAN LYMPHOMA IS CLOSE TO THE LIGAND-BINDING SITE
Takahashi, S., Esserman, L., & Levy, R. (1991). AN EPITOPE ON THE TRANSFERRIN RECEPTOR PREFERENTIALLY EXPOSED DURING TUMOR PROGRESSION IN HUMAN LYMPHOMA IS CLOSE TO THE LIGAND-BINDING SITE. BLOOD, 77(4), 826–832.

Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines
Kanter, G., Yang, J., Voloshin, A., Levy, S., Swartz, J. R., & Levy, R. (2007). Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. BLOOD, 109(8), 3393–99.

Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms
Natkunam, Y., Vainer, G., Chen, J., Zhao, S., Marinelli, R. J., Hammer, A. S., … Lossos, I. S. (2007). Expression of the RNA-binding protein VICKZ in normal hematopoietic tissues and neoplasms. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 92(2), 176–83.

DIVERSITY OF T-CELL ANTIGEN RECEPTOR VARIABLE GENES USED BY MYCOSIS-FUNGOIDES CELLS
Bahler, D. W., Berry, G., Oksenberg, J., Warnke, R. A., & Levy, R. (1992). DIVERSITY OF T-CELL ANTIGEN RECEPTOR VARIABLE GENES USED BY MYCOSIS-FUNGOIDES CELLS. AMERICAN JOURNAL OF PATHOLOGY, 140(1), 1–8.

INTERLEUKIN-3 IS A GROWTH-FACTOR FOR HUMAN FOLLICULAR B-CELL LYMPHOMA
CLAYBERGER, C., LUNAFINEMAN, S., Lee, J. E., Pillai, A., Campbell, M., Levy, R., & KRENSKY, A. M. (1992). INTERLEUKIN-3 IS A GROWTH-FACTOR FOR HUMAN FOLLICULAR B-CELL LYMPHOMA. JOURNAL OF EXPERIMENTAL MEDICINE, 175(2), 371–76.

Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand
Liu, A., Guardino, A., Chinsangararn, L., Goldstein, M. J., Panicali, D., & Levy, R. (2007). Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand. CANCER RESEARCH, 67(14), 7037–44.

"Minor" BCL2 breakpoints in follicular lymphoma - Frequency and correlation with grade and disease presentation in 236 cases
Weinberg, O. K., Ai, W. Z., Mariappan, M. R., Shum, C., Levy, R., & Arber, D. A. (2007). "Minor" BCL2 breakpoints in follicular lymphoma - Frequency and correlation with grade and disease presentation in 236 cases. JOURNAL OF MOLECULAR DIAGNOSTICS, 9(4), 530–37.

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself
Li, J., Song, W., Czerwinski, D. K., Varghese, B., Uematsu, S., Akira, S., … Levy, R. (2007). Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. JOURNAL OF IMMUNOLOGY, 179(4), 2493–2500.

IDIOTYPE VACCINATION POST-BONE MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA - INITIAL STUDIES IN A MURINE MODEL
Kwak, L. W., Campbell, M., & Levy, R. (1991). IDIOTYPE VACCINATION POST-BONE MARROW TRANSPLANTATION FOR B-CELL LYMPHOMA - INITIAL STUDIES IN A MURINE MODEL. CANCER DETECTION AND PREVENTION, 15(4), 323–325.

LMO2 protein expression predicts survival in patients with diffuse large B-Cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab
Natkunam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., … Lossos, I. S. (2008). LMO2 protein expression predicts survival in patients with diffuse large B-Cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. JOURNAL OF CLINICAL ONCOLOGY, 26(3), 447–54.

TRANSFER OF SPECIFIC IMMUNITY TO B-CELL LYMPHOMA WITH SYNGENEIC BONE-MARROW IN MICE - A STRATEGY FOR USING AUTOLOGOUS MARROW AS AN ANTITUMOR THERAPY
Kwak, L. W., Campbell, M. J., Zelenetz, A. D., & Levy, R. (1991). TRANSFER OF SPECIFIC IMMUNITY TO B-CELL LYMPHOMA WITH SYNGENEIC BONE-MARROW IN MICE - A STRATEGY FOR USING AUTOLOGOUS MARROW AS AN ANTITUMOR THERAPY. BLOOD, 78(10), 2768–2772.

Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis
Baecklund, E., Natkunam, Y., Backlin, C., Iliadou, A., Askling, J., Ekbom, A., … Rosenquist, R. (2008). Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. BRITISH JOURNAL OF HAEMATOLOGY, 141(1), 69–72.

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP
Malumbres, R., Chen, J., Tibshirani, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., … Lossos, I. S. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. BLOOD, 111(12), 5509–14.

Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
McCormick, A. A., Reddy, S., Reinl, S. J., Cameron, T. I., Czerwinkski, D. K., Vojdani, F., … Levy, R. (2008). Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(29), 10131–36.

Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors
Brody, J. D., Goldstein, M. J., Czerwinski, D. K., & Levy, R. (2009). Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. BLOOD, 113(1), 85–94.

Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells
Ai, W. Z., Hou, L.-Z., Zeiser, R., Czerwinski, D., Negrin, R. S., & Levy, R. (2009). Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells. INTERNATIONAL JOURNAL OF CANCER, 124(1), 239–44.

ENHANCED DETECTION OF THE T(14-18) TRANSLOCATION IN MALIGNANT-LYMPHOMA USING PULSED-FIELD GEL-ELECTROPHORESIS
Zelenetz, A. D., Chu, G., Galili, N., Bangs, C. D., Horning, S. J., Donlon, T. A., … Levy, R. (1991). ENHANCED DETECTION OF THE T(14-18) TRANSLOCATION IN MALIGNANT-LYMPHOMA USING PULSED-FIELD GEL-ELECTROPHORESIS. BLOOD, 78(6), 1552–60.

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Racila, E., Link, B. K., Weng, W.-K., Witzig, T. E., Ansell, S., Maurer, M. J., … Weiner, G. J. (2008). A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. CLINICAL CANCER RESEARCH, 14(20), 6697–6703.

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy
Houot, R., & Levy, R. (2009). T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. BLOOD, 113(15), 3546–52.

Vaccines for lymphomas: Idiotype vaccines and beyond
Houot, R., & Levy, R. (2009). Vaccines for lymphomas: Idiotype vaccines and beyond. BLOOD REVIEWS, 23(3), 137–42.

HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LYMPHOMA REPRESENTS TUMOR PROGRESSION BY A SINGLE MALIGNANT B-CELL
Zelenetz, A. D., Chen, T. T., & Levy, R. (1991). HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LYMPHOMA REPRESENTS TUMOR PROGRESSION BY A SINGLE MALIGNANT B-CELL. JOURNAL OF EXPERIMENTAL MEDICINE, 173(1), 197–207.

IG VH GENE-EXPRESSION AMONG HUMAN FOLLICULAR LYMPHOMAS
Bahler, D. W., Campbell, M. J., Hart, S., MILLER, R. A., Levy, S., & Levy, R. (1991). IG VH GENE-EXPRESSION AMONG HUMAN FOLLICULAR LYMPHOMAS. BLOOD, 78(6), 1561–1568.

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma
Timmerman, J. M., Vose, J. M., Czerwinski, D. K., Weng, W.-K., Ingolia, D., Mayo, M., … Levy, R. (2009). Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 50(1), 37–46.

The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms and Selected Other Entities
Gratzinger, D., Zhao, S., West, R., Rouse, R. V., Vogel, H., Gil, E. C., … Natkunam, Y. (2009). The Transcription Factor LMO2 Is a Robust Marker of Vascular Endothelium and Vascular Neoplasms and Selected Other Entities. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 131(2), 264–78.

Idiotype vaccination for lymphoma: moving towards optimisation
Houot, R., & Levy, R. (2009). Idiotype vaccination for lymphoma: moving towards optimisation. LEUKEMIA & LYMPHOMA, 50(1), 1–2.

Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab
Weng, W.-K., & Levy, R. (2009). Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. LEUKEMIA & LYMPHOMA, 50(5), 723–27.

Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma
Alizadeh, A. A., Gentles, A. J., Lossos, I. S., & Levy, R. (2009). Molecular Outcome Prediction in Diffuse Large-B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 360(26), 2794–95.

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion
Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., … Levy, R. (2009). Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by T-reg depletion. BLOOD, 114(16), 3431–38.

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma
Weng, W.-K., & Levy, R. (2009). Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. LEUKEMIA & LYMPHOMA, 50(9), 1494–1500.

INDUCTION OF PROLIFERATION OF HUMAN FOLLICULAR (B-TYPE) LYMPHOMA-CELLS BY COGNATE INTERACTION WITH CD4+ T-CELL CLONES
Umetsu, D. T., Esserman, L., Donlon, T. A., DeKruyff, R. H., & Levy, R. (1990). INDUCTION OF PROLIFERATION OF HUMAN FOLLICULAR (B-TYPE) LYMPHOMA-CELLS BY COGNATE INTERACTION WITH CD4+ T-CELL CLONES. JOURNAL OF IMMUNOLOGY, 144(7), 2550–2557.

Generation of CD8(+) T cell-mediated immunity against idiotype-negative lymphoma escapees
Varghese, B., Widman, A., Do, J., Taidi, B., Czerwinski, D. K., Timmerman, J., … Levy, R. (2009). Generation of CD8(+) T cell-mediated immunity against idiotype-negative lymphoma escapees. BLOOD, 114(20), 4477–85.

OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES
Knox, S. J., Levy, R., Hodgkinson, S., Bell, R., Brown, S., Wood, G. S., … Reichert, T. (1991). OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL-ANTIBODY IN PATIENTS WITH MYCOSIS-FUNGOIDES. BLOOD, 77(1), 20–30.

Cell-free production of Gaussia princeps luciferase - antibody fragment bioconjugates for ex vivo detection of tumor cells
Patel, K. G., Ng, P. P., Kuo, C.-C., Levy, S., Levy, R., & Swartz, J. R. (2009). Cell-free production of Gaussia princeps luciferase - antibody fragment bioconjugates for ex vivo detection of tumor cells. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 390(3), 971–76.

AN EXPERIMENTAL COMPARTMENTAL FLOW MODEL FOR ASSESSING THE HEMODYNAMIC-RESPONSE OF INTRACRANIAL ARTERIOVENOUS-MALFORMATIONS TO STEREOTAXIC RADIOSURGERY
Lo, E. H., FABRIKANT, J. I., Levy, R. P., Phillips, M. H., Frankel, K. A., & ALPEN, E. L. (1991). AN EXPERIMENTAL COMPARTMENTAL FLOW MODEL FOR ASSESSING THE HEMODYNAMIC-RESPONSE OF INTRACRANIAL ARTERIOVENOUS-MALFORMATIONS TO STEREOTAXIC RADIOSURGERY. NEUROSURGERY, 28(2), 251–259.

CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas
Luo, R. F., Zhao, S., Tibshirani, R., Myklebust, J. H., Sanyal, M., Fernandez, R., … Natkunam, Y. (2010). CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. HUMAN PATHOLOGY, 41(2), 271–80.

C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia
Anderson, M. W., Zhao, S., Ai, W. Z., Tibshirani, R., Levy, R., Lossos, I. S., & Natkunam, Y. (2010). C-C Chemokine Receptor 1 Expression in Human Hematolymphoid Neoplasia. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 133(3), 473–83.

FOLLICULAR LYMPHOMA - A MODEL OF LYMPHOID TUMOR PROGRESSION IN MAN
Zelenetz, A. D., Campbell, M. J., Bahler, D. W., Takahashi, S., Oren, R., Esserman, L., … Levy, R. (1991). FOLLICULAR LYMPHOMA - A MODEL OF LYMPHOID TUMOR PROGRESSION IN MAN. Presented at the 4TH INTERNATIONAL CONF ON MALIGNANT LYMPHOMA, LUGANO,SWITZERLAND,SWITZERLAND: KLUWER ACADEMIC PUBL.

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression
Irish, J. M., Myklebust, J. H., Alizadeh, A. A., Houot, R., Sharman, J. P., Czerwinski, D. K., … Levy, R. (2010). B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 107(29), 12747–54.

Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant
Brody, J., & Levy, R. (2009). Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. IMMUNOTHERAPY, 1(5), 809–24.

Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma
Durnick, D. K., Law, M. E., Maurer, M. J., Natkunam, Y., Levy, R., Lossos, I. S., … McPhail, E. D. (2010). Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 134(2), 278–81.

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., Advani, R. H., … Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324–32.

Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components
Younes, S. F., Beck, A. H., Lossos, I. S., Levy, R., Warnke, R. A., & Natkunam, Y. (2010). Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular and Diffuse Components. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 34(9), 1266–76.

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., … Majeti, R. (2010). Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma. CELL, 142(5), 699–713.

Escherichia coli-based production of a tumor idiotype antibody fragment - tetanus toxin fragment C fusion protein vaccine for B cell lymphoma
Patel, K. G., Ng, P. P., Levy, S., Levy, R., & Swartz, J. R. (2011). Escherichia coli-based production of a tumor idiotype antibody fragment - tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. PROTEIN EXPRESSION AND PURIFICATION, 75(1), 15–20.

A CpG-loaded tumor cell vaccine induces antitumor CD4(+) T cells that are effective in adoptive therapy for large and established tumors
Goldstein, M. J., Varghese, B., Brody, J. D., Rajapaksa, R., Kohrt, H., Czerwinski, D. K., … Levy, R. (2011). A CpG-loaded tumor cell vaccine induces antitumor CD4(+) T cells that are effective in adoptive therapy for large and established tumors. BLOOD, 117(1), 118–27.

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., … Levy, R. (2011). CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. BLOOD, 117(8), 2423–32.

Cytokine fusion constructs as DNA vaccines against tumors.
Maecker, H. T., Syrengelas, A., & Levy, R. (2000). Cytokine fusion constructs as DNA vaccines against tumors. Methods in Molecular Medicine, 29, 221–239.

Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results
Brody, J., Kohrt, H., Marabelle, A., & Levy, R. (2011). Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results. JOURNAL OF CLINICAL ONCOLOGY, 29(14), 1864–75.

The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow
Younes, S. F., Beck, A. H., Ohgami, R. S., Lossos, I. S., Levy, R., Warnke, R. A., & Natkunam, Y. (2011). The Efficacy of HGAL and LMO2 in the Separation of Lymphomas Derived From Small B Cells in Nodal and Extranodal Sites, Including the Bone Marrow. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 135(5), 697–708.

DIRECTIONAL CLONING OF CDNA USING A SELECTABLE SFII CASSETTE
Zelenetz, A. D., & Levy, R. (1990). DIRECTIONAL CLONING OF CDNA USING A SELECTABLE SFII CASSETTE. GENE, 89(1), 123–127.

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Liu, C. L., Kohrt, H. E., Houot, R., … Levy, R. (2011). Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. BLOOD, 118(5), 1350–58.

Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.
Morton, L. M., Cerhan, J. R., Hartge, P., Vasef, M. A., Neppalli, V. T., Natkunam, Y., … Wang, S. S. (2011). Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. International Journal of Molecular Epidemiology and Genetics, 2(3), 245–52.

Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells
Goldstein, M. J., Kohrt, H. E., Houot, R., Varghese, B., Lin, J. T., Swanson, E., & Levy, R. (2012). Adoptive Cell Therapy for Lymphoma with CD4 T Cells Depleted of CD137-Expressing Regulatory T Cells. CANCER RESEARCH, 72(5), 1239–47.

Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81
Sagi, Y., Landrigan, A., Levy, R., & Levy, S. (2012). Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(5), 1613–18.

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., … Levy, R. (2012). Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. JOURNAL OF CLINICAL INVESTIGATION, 122(3), 1066–75.

COMBINED SYNGENEIC BONE-MARROW TRANSPLANTATION AND IMMUNOTHERAPY OF A MURINE B-CELL LYMPHOMA - ACTIVE IMMUNIZATION WITH TUMOR-DERIVED IDIOTYPIC IMMUNOGLOBULIN
Kwak, L. W., Campbell, M. J., Zelenetz, A. D., & Levy, R. (1990). COMBINED SYNGENEIC BONE-MARROW TRANSPLANTATION AND IMMUNOTHERAPY OF A MURINE B-CELL LYMPHOMA - ACTIVE IMMUNIZATION WITH TUMOR-DERIVED IDIOTYPIC IMMUNOGLOBULIN. BLOOD, 76(11), 2411–2417.

Combination strategies to enhance antitumor ADCC
Kohrt, H. E., Houot, R., Marabelle, A., Cho, H. J., Osman, K., Goldstein, M., … Brody, J. (2012). Combination strategies to enhance antitumor ADCC. IMMUNOTHERAPY, 4(5), 511–27.

A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity
Ng, P. P., Jia, M., Patel, K. G., Brody, J. D., Swartz, J. R., Levy, S., & Levy, R. (2012). A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(36), 14526–31.

CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications
Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., … Natkunam, Y. (2012). CD137 Is Expressed in Follicular Dendritic Cell Tumors and in Classical Hodgkin and T-Cell Lymphomas Diagnostic and Therapeutic Implications. AMERICAN JOURNAL OF PATHOLOGY, 181(3), 795–803.

IDIOTYPIC VARIATION IN A HUMAN B-LYMPHOMA CELL-LINE
Berinstein, N., Campbell, M. J., Lam, K., CARSWELL, C., Levy, S., & Levy, R. (1990). IDIOTYPIC VARIATION IN A HUMAN B-LYMPHOMA CELL-LINE. JOURNAL OF IMMUNOLOGY, 144(2), 752–758.

Self-antigen recognition by follicular lymphoma B-cell receptors
Sachen, K. L., Strohman, M. J., Singletary, J., Alizadeh, A. A., Kattah, N. H., Lossos, C., … Levy, R. (2012). Self-antigen recognition by follicular lymphoma B-cell receptors. BLOOD, 120(20), 4182–90.

Cancer Vaccines and T Cell Therapy
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(1), S97–S101.

Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Kihira, S., Liu, C. L., … Alizadeh, A. A. (2013). Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood, 121(9), 1604–11.

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
Myklebust, J. H., Irish, J. M., Brody, J., Czerwinski, D. K., Houot, R., Kohrt, H. E., … Levy, R. (2013). High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood, 121(8), 1367–76.

STEREOTAXIC HEAVY-CHARGED-PARTICLE BRAGG-PEAK RADIATION FOR INTRACRANIAL ARTERIOVENOUS-MALFORMATIONS
Steinberg, G. K., FABRIKANT, J. I., Marks, M. P., Levy, R. P., Frankel, K. A., Phillips, M. H., … Silverberg, G. D. (1990). STEREOTAXIC HEAVY-CHARGED-PARTICLE BRAGG-PEAK RADIATION FOR INTRACRANIAL ARTERIOVENOUS-MALFORMATIONS. NEW ENGLAND JOURNAL OF MEDICINE, 323(2), 96–101.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., … Levy, R. (2013). Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. JOURNAL OF CLINICAL INVESTIGATION, 123(6), 2447–63.

IDIOTYPE VACCINATION AGAINST MURINE B-CELL LYMPHOMA - HUMORAL AND CELLULAR-REQUIREMENTS FOR THE FULL EXPRESSION OF ANTITUMOR IMMUNITY
Campbell, M. J., Esserman, L., BYARS, N. E., Allison, A. C., & Levy, R. (1990). IDIOTYPE VACCINATION AGAINST MURINE B-CELL LYMPHOMA - HUMORAL AND CELLULAR-REQUIREMENTS FOR THE FULL EXPRESSION OF ANTITUMOR IMMUNITY. JOURNAL OF IMMUNOLOGY, 145(3), 1029–1036.

DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES
Knox, S. J., Levy, R., MILLER, R. A., UHLAND, W., Schiele, J., RUEHL, W., … Goris, M. L. (1990). DETERMINANTS OF THE ANTITUMOR EFFECT OF RADIOLABELED MONOCLONAL-ANTIBODIES. CANCER RESEARCH, 50(16), 4935–4940.

TAPA-1, THE TARGET OF AN ANTIPROLIFERATIVE ANTIBODY, IS ASSOCIATED ON THE CELL-SURFACE WITH THE LEU-13 ANTIGEN
Takahashi, S., Doss, C., Levy, S., & Levy, R. (1990). TAPA-1, THE TARGET OF AN ANTIPROLIFERATIVE ANTIBODY, IS ASSOCIATED ON THE CELL-SURFACE WITH THE LEU-13 ANTIGEN. JOURNAL OF IMMUNOLOGY, 145(7), 2207–2213.

ISOLATION OF ANTIIDIOTYPIC ANTIBODIES TO T-CELLS USING AN ANTI-FRAMEWORK DETERMINANT ANTIBODY
Maecker, H. T., Kitamura, K., Brenner, M. B., & Levy, R. (1987). ISOLATION OF ANTIIDIOTYPIC ANTIBODIES TO T-CELLS USING AN ANTI-FRAMEWORK DETERMINANT ANTIBODY. JOURNAL OF IMMUNOLOGICAL METHODS, 98(2), 219–226.

COMPARISON OF COMBINATIONS OF INTERFERONS WITH TUMOR SPECIFIC AND NONSPECIFIC MONOCLONAL-ANTIBODIES AS THERAPY FOR MURINE B-CELL AND T-CELL LYMPHOMAS
BASHAM, T. Y., Palladino, M. A., BADGER, C. C., Bernstein, I. D., Levy, R., & Merigan, T. C. (1988). COMPARISON OF COMBINATIONS OF INTERFERONS WITH TUMOR SPECIFIC AND NONSPECIFIC MONOCLONAL-ANTIBODIES AS THERAPY FOR MURINE B-CELL AND T-CELL LYMPHOMAS. CANCER RESEARCH, 48(15), 4196–4200.

TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-IDIOTYPE ANTIBODIES ALONE AND IN COMBINATION WITH ALPHA INTERFERON
Brown, S. L., MILLER, R. A., Horning, S. J., Czerwinski, D., Hart, S. M., MCELDERRY, R., … Levy, R. (1989). TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-IDIOTYPE ANTIBODIES ALONE AND IN COMBINATION WITH ALPHA INTERFERON. BLOOD, 73(3), 651–661.

AN EPITOPE OF THE TRANSFERRIN RECEPTOR IS EXPOSED ON THE CELL-SURFACE OF HIGH-GRADE BUT NOT LOW-GRADE HUMAN LYMPHOMAS
Esserman, L., Takahashi, S., Rojas, V., Warnke, R., & Levy, R. (1989). AN EPITOPE OF THE TRANSFERRIN RECEPTOR IS EXPOSED ON THE CELL-SURFACE OF HIGH-GRADE BUT NOT LOW-GRADE HUMAN LYMPHOMAS. BLOOD, 74(8), 2718–2729.

ACTIVATION OF AN EXCLUDED IMMUNOGLOBULIN ALLELE IN A HUMAN B-LYMPHOMA CELL-LINE
Berinstein, N., Levy, S., & Levy, R. (1989). ACTIVATION OF AN EXCLUDED IMMUNOGLOBULIN ALLELE IN A HUMAN B-LYMPHOMA CELL-LINE. SCIENCE, 244(4902), 337–339.

FUNCTIONAL IMMUNOGLOBULIN LIGHT CHAIN GENES ARE REPLACED BY ONGOING REARRANGEMENTS OF GERMLINE VK GENES TO DOWNSTREAM JK SEGMENTS IN A MURINE B-CELL LINE
Levy, S., Campbell, M. J., & Levy, R. (1989). FUNCTIONAL IMMUNOGLOBULIN LIGHT CHAIN GENES ARE REPLACED BY ONGOING REARRANGEMENTS OF GERMLINE VK GENES TO DOWNSTREAM JK SEGMENTS IN A MURINE B-CELL LINE. JOURNAL OF EXPERIMENTAL MEDICINE, 170(1), 1–13.

Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor.
Campbell, M. J., Esserman, L., BYARS, N. E., Allison, A. C., & Levy, R. (1989). Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. International Reviews of Immunology, 4(4), 251–270.

DNA FRAGMENTATION AND CELL-DEATH MEDIATED BY T-CELL ANTIGEN RECEPTOR CD3 COMPLEX ON A LEUKEMIA T-CELL LINE
Takahashi, S., Maecker, H. T., & Levy, R. (1989). DNA FRAGMENTATION AND CELL-DEATH MEDIATED BY T-CELL ANTIGEN RECEPTOR CD3 COMPLEX ON A LEUKEMIA T-CELL LINE. EUROPEAN JOURNAL OF IMMUNOLOGY, 19(10), 1911–1919.

CYTO-TOXIC LYMPHOCYTE-T SPECIFIC FOR SELF TUMOR IMMUNOGLOBULIN EXPRESS T-CELL RECEPTOR DELTA-CHAIN
Wright, A., Lee, J. E., Link, M. P., Smith, S. D., Carroll, W., Levy, R., … KRENSKY, A. M. (1989). CYTO-TOXIC LYMPHOCYTE-T SPECIFIC FOR SELF TUMOR IMMUNOGLOBULIN EXPRESS T-CELL RECEPTOR DELTA-CHAIN. JOURNAL OF EXPERIMENTAL MEDICINE, 169(5), 1557–64.

ANTIIDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA
Brown, S. L., MILLER, R. A., & Levy, R. (1989). ANTIIDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA. SEMINARS IN ONCOLOGY, 16(3), 199–210.

PREVALENCE OF ANTIGEN RECEPTOR VARIANTS IN HUMAN T-CELL LINES AND TUMORS
Maecker, H. T., & Levy, R. (1989). PREVALENCE OF ANTIGEN RECEPTOR VARIANTS IN HUMAN T-CELL LINES AND TUMORS. JOURNAL OF IMMUNOLOGY, 142(4), 1395–1404.

SYNERGISTIC ANTITUMOR-ACTIVITY WITH IFN AND MONOCLONAL ANTI-IDIOTYPE FOR MURINE B-CELL LYMPHOMA - MECHANISM OF ACTION
BASHAM, T. Y., RACE, E. R., Campbell, M. J., Reid, T. R., Levy, R., & Merigan, T. C. (1988). SYNERGISTIC ANTITUMOR-ACTIVITY WITH IFN AND MONOCLONAL ANTI-IDIOTYPE FOR MURINE B-CELL LYMPHOMA - MECHANISM OF ACTION. JOURNAL OF IMMUNOLOGY, 141(8), 2855–2860.

MUTATIONAL HOT SPOTS IN IG V-REGION GENES OF HUMAN FOLLICULAR LYMPHOMAS
Levy, S., Mendel, E., Kon, S., Avnur, Z., & Levy, R. (1988). MUTATIONAL HOT SPOTS IN IG V-REGION GENES OF HUMAN FOLLICULAR LYMPHOMAS. JOURNAL OF EXPERIMENTAL MEDICINE, 168(2), 475–489.

IMMUNOTHERAPY OF ESTABLISHED MURINE B-CELL LYMPHOMA - COMBINATION OF IDIOTYPE IMMUNIZATION AND CYCLOPHOSPHAMIDE
Campbell, M. J., Esserman, L., & Levy, R. (1988). IMMUNOTHERAPY OF ESTABLISHED MURINE B-CELL LYMPHOMA - COMBINATION OF IDIOTYPE IMMUNIZATION AND CYCLOPHOSPHAMIDE. JOURNAL OF IMMUNOLOGY, 141(9), 3227–3233.

SINGLE CELL ORIGIN OF BIGENOTYPIC AND BIPHENOTYPIC B-CELL PROLIFERATIONS IN HUMAN FOLLICULAR LYMPHOMAS
Cleary, M. L., Galili, N., Trela, M., Levy, R., & Sklar, J. (1988). SINGLE CELL ORIGIN OF BIGENOTYPIC AND BIPHENOTYPIC B-CELL PROLIFERATIONS IN HUMAN FOLLICULAR LYMPHOMAS. JOURNAL OF EXPERIMENTAL MEDICINE, 167(2), 582–597.

IDIOTYPE AS A TUMOR-SPECIFIC MARKER IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA
Carroll, W. L., Link, M. P., Cleary, M. L., Bologna, S., CARSWELL, C., Amylon, M. D., … Levy, R. (1988). IDIOTYPE AS A TUMOR-SPECIFIC MARKER IN CHILDHOOD B-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA. BLOOD, 71(4), 1068–1073.

HETEROGENEITY OF A MURINE B-CELL LYMPHOMA - ISOLATION AND CHARACTERIZATION OF IDIOTYPIC VARIANTS
Starnes, C. O., Carroll, W. L., Campbell, M. J., Houston, L. L., Apell, G., & Levy, R. (1988). HETEROGENEITY OF A MURINE B-CELL LYMPHOMA - ISOLATION AND CHARACTERIZATION OF IDIOTYPIC VARIANTS. JOURNAL OF IMMUNOLOGY, 141(1), 333–339.

ALTERNATIVE V-KAPPA GENE REARRANGEMENTS IN A MURINE B-CELL LYMPHOMA - AN EXPLANATION FOR IDIOTYPIC HETEROGENEITY
Carroll, W. L., Starnes, C. O., Levy, R., & Levy, S. (1988). ALTERNATIVE V-KAPPA GENE REARRANGEMENTS IN A MURINE B-CELL LYMPHOMA - AN EXPLANATION FOR IDIOTYPIC HETEROGENEITY. JOURNAL OF EXPERIMENTAL MEDICINE, 168(5), 1607–1620.

SPECIFIC ENHANCEMENT OF THE THERAPEUTIC EFFECT OF ANTI-IDIOTYPE ANTIBODIES ON A MURINE B-CELL LYMPHOMA BY IL-2
Berinstein, N., Starnes, C. O., & Levy, R. (1988). SPECIFIC ENHANCEMENT OF THE THERAPEUTIC EFFECT OF ANTI-IDIOTYPE ANTIBODIES ON A MURINE B-CELL LYMPHOMA BY IL-2. JOURNAL OF IMMUNOLOGY, 140(8), 2839–2845.

SPONTANEOUS T-CELL ANTIGEN RECEPTOR VARIANTS OF A HUMAN T-LEUKEMIA CELL-LINE
Maecker, H. T., & Levy, R. (1988). SPONTANEOUS T-CELL ANTIGEN RECEPTOR VARIANTS OF A HUMAN T-LEUKEMIA CELL-LINE. JOURNAL OF IMMUNOLOGY, 141(9), 2994–3002.

ANTI-IDIOTYPE ANTIBODIES REVEAL THE EXISTENCE OF SOMATIC MUTATION IN HUMAN B-CELL LYMPHOMA
Levy, R., Levy, S., Brown, S. L., Kon, S., & Carroll, W. (1987). ANTI-IDIOTYPE ANTIBODIES REVEAL THE EXISTENCE OF SOMATIC MUTATION IN HUMAN B-CELL LYMPHOMA. MONOGRAPHS IN ALLERGY, 22, 194–203.

A UNIQUE ANTIGEN ON MATURE B-CELLS DEFINED BY A MONOCLONAL-ANTIBODY
Link, M. P., Bindl, J., MEEKER, T. C., CARSWELL, C., DOSS, C. A., Warnke, R. A., & Levy, R. (1986). A UNIQUE ANTIGEN ON MATURE B-CELLS DEFINED BY A MONOCLONAL-ANTIBODY. JOURNAL OF IMMUNOLOGY, 137(9), 3013–3018.

IDIOTYPE VACCINATION AGAINST MURINE B-CELL LYMPHOMA - HUMORAL AND CELLULAR-RESPONSES ELICITED BY TUMOR-DERIVED IMMUNOGLOBULIN-M AND ITS MOLECULAR SUBUNITS
Campbell, M. J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J. B., Levy, S., & Levy, R. (1987). IDIOTYPE VACCINATION AGAINST MURINE B-CELL LYMPHOMA - HUMORAL AND CELLULAR-RESPONSES ELICITED BY TUMOR-DERIVED IMMUNOGLOBULIN-M AND ITS MOLECULAR SUBUNITS. JOURNAL OF IMMUNOLOGY, 139(8), 2825–2833.

PRELIMINARY-OBSERVATIONS ON EFFECT OF HUMAN LEUKOCYTE INTERFERON IN NON-HODGKINS LYMPHOMA
Merigan, T. C., Sikora, K., BREEDEN, J. H., Levy, R., & Rosenberg, S. A. (1978). PRELIMINARY-OBSERVATIONS ON EFFECT OF HUMAN LEUKOCYTE INTERFERON IN NON-HODGKINS LYMPHOMA. NEW ENGLAND JOURNAL OF MEDICINE, 299(26), 1449–1453.

ANTIBODY-DIRECTED TARGETING OF LIPOSOMES TO HUMAN CELL-LINES - ROLE OF BINDING AND INTERNALIZATION ON GROWTH-INHIBITION
Berinstein, N., Matthay, K. K., Papahadjopoulos, D., Levy, R., & Sikic, B. I. (1987). ANTIBODY-DIRECTED TARGETING OF LIPOSOMES TO HUMAN CELL-LINES - ROLE OF BINDING AND INTERNALIZATION ON GROWTH-INHIBITION. CANCER RESEARCH, 47(22), 5954–5959.

SYNERGISTIC ANTITUMOR EFFECT OF INTERFERON AND ANTIIDIOTYPE MONOCLONAL-ANTIBODY IN MURINE LYMPHOMA
BASHAM, T. Y., Kaminski, M. S., Kitamura, K., Levy, R., & Merigan, T. C. (1986). SYNERGISTIC ANTITUMOR EFFECT OF INTERFERON AND ANTIIDIOTYPE MONOCLONAL-ANTIBODY IN MURINE LYMPHOMA. JOURNAL OF IMMUNOLOGY, 137(9), 3019–3024.

INHIBITION OF LYMPHOMA HYBRIDS BY HUMAN INTERFERON
Sikora, K., Dilley, J., Merigan, T., BASHAM, T., & Levy, R. (1980). INHIBITION OF LYMPHOMA HYBRIDS BY HUMAN INTERFERON. LANCET, 2(8200), 891–893.

PAN-LEUKOCYTE MONOCLONAL ANTIBODY-L3B12 - CHARACTERIZATION AND APPLICATION TO RESEARCH AND DIAGNOSTIC PROBLEMS
Wood, G. S., Link, M., Warnke, R. A., Dilley, J., & Levy, R. (1984). PAN-LEUKOCYTE MONOCLONAL ANTIBODY-L3B12 - CHARACTERIZATION AND APPLICATION TO RESEARCH AND DIAGNOSTIC PROBLEMS. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 81(2), 176–183.

A UNIQUE HUMAN LYMPHOCYTE-B ANTIGEN DEFINED BY A MONOCLONAL-ANTIBODY
MEEKER, T. C., MILLER, R. A., Link, M. P., Bindl, J., Warnke, R., & Levy, R. (1984). A UNIQUE HUMAN LYMPHOCYTE-B ANTIGEN DEFINED BY A MONOCLONAL-ANTIBODY. HYBRIDOMA, 3(4), 305–320.

A SINGLE MONOCLONAL-ANTIBODY IDENTIFIES T-CELL LINEAGE OF CHILDHOOD LYMPHOID MALIGNANCIES
Link, M., Warnke, R., Finlay, J., Amylon, M., Miller, R., Dilley, J., & Levy, R. (1983). A SINGLE MONOCLONAL-ANTIBODY IDENTIFIES T-CELL LINEAGE OF CHILDHOOD LYMPHOID MALIGNANCIES. BLOOD, 62(4), 722–728.

LYMPHOMA REGRESSION INDUCED BY MONOCLONAL ANTIIDIOTYPIC ANTIBODIES CORRELATES WITH THEIR ABILITY TO INDUCE IG SIGNAL-TRANSDUCTION AND IS NOT PREVENTED BY TUMOR EXPRESSION OF HIGH-LEVELS OF BCL-2 PROTEIN
Vuist, W. M. J., Levy, R., & Maloney, D. G. (1994). LYMPHOMA REGRESSION INDUCED BY MONOCLONAL ANTIIDIOTYPIC ANTIBODIES CORRELATES WITH THEIR ABILITY TO INDUCE IG SIGNAL-TRANSDUCTION AND IS NOT PREVENTED BY TUMOR EXPRESSION OF HIGH-LEVELS OF BCL-2 PROTEIN. BLOOD, 83(4), 899–906.

PHASE-I CLINICAL-TRIAL USING ESCALATING SINGLE-DOSE INFUSION OF CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8) IN PATIENTS WITH RECURRENT B-CELL LYMPHOMA
Maloney, D. G., Liles, T. M., Czerwinski, D. K., WALDICHUK, C., Rosenberg, J., GRILLOLOPEZ, A., & Levy, R. (1994). PHASE-I CLINICAL-TRIAL USING ESCALATING SINGLE-DOSE INFUSION OF CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY (IDEC-C2B8) IN PATIENTS WITH RECURRENT B-CELL LYMPHOMA. BLOOD, 84(8), 2457–2466.

IDIOTYPE-CYTOKINE FUSION PROTEINS AS CANCER VACCINES - RELATIVE EFFICACY OF IL-2, IL-4, AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
Chen, T. T., Tao, M. H., & Levy, R. (1994). IDIOTYPE-CYTOKINE FUSION PROTEINS AS CANCER VACCINES - RELATIVE EFFICACY OF IL-2, IL-4, AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR. JOURNAL OF IMMUNOLOGY, 153(10), 4775–87.

PREFERENTIAL USE OF THE VH4 IG GENE FAMILY BY DIFFUSE LARGE-CELL LYMPHOMA
Hsu, F. J., & Levy, R. (1995). PREFERENTIAL USE OF THE VH4 IG GENE FAMILY BY DIFFUSE LARGE-CELL LYMPHOMA. BLOOD, 86(8), 3072–3082.

B-LYMPHOMA CELLS ARE ACTIVATED BY PEPTIDE LIGANDS OF THE ANTIGEN-BINDING RECEPTOR OR BY ANTIIDIOTYPIC ANTIBODY TO INDUCE EXTRACELLULAR ACIDIFICATION
Renschler, M. F., Wada, H. G., Fok, K. S., & Levy, R. (1995). B-LYMPHOMA CELLS ARE ACTIVATED BY PEPTIDE LIGANDS OF THE ANTIGEN-BINDING RECEPTOR OR BY ANTIIDIOTYPIC ANTIBODY TO INDUCE EXTRACELLULAR ACIDIFICATION. CANCER RESEARCH, 55(23), 5642–5647.

INDUCTION OF AUTOANTIBODY RESPONSES TO GM-CSF BY HYPERIMMUNIZATION WITH AN ID-GM-CSF FUSION PROTEIN
Chen, T. T., & Levy, R. (1995). INDUCTION OF AUTOANTIBODY RESPONSES TO GM-CSF BY HYPERIMMUNIZATION WITH AN ID-GM-CSF FUSION PROTEIN. JOURNAL OF IMMUNOLOGY, 154(7), 3105–17.

SYNTHETIC PEPTIDE LIGANDS OF THE ANTIGEN-BINDING RECEPTOR INDUCE PROGRAMMED CELL-DEATH IN A HUMAN B-CELL LYMPHOMA
Renschler, M. F., Bhatt, R. R., Dower, W. J., & Levy, R. (1994). SYNTHETIC PEPTIDE LIGANDS OF THE ANTIGEN-BINDING RECEPTOR INDUCE PROGRAMMED CELL-DEATH IN A HUMAN B-CELL LYMPHOMA. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 91(9), 3623–3627.

CLINICAL-TRIALS OF IDIOTYPE-SPECIFIC VACCINE IN B-CELL LYMPHOMAS
Hsu, F. J., Kwak, L., Campbell, M., LILES, T., Czerwinski, D., Hart, S., … Levy, R. (1993). CLINICAL-TRIALS OF IDIOTYPE-SPECIFIC VACCINE IN B-CELL LYMPHOMAS. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 690, 385–387.

EVALUATION OF THE COULTER STKS 5-PART DIFFERENTIAL
Cornbleet, P. J., Myrick, D., & Levy, R. (1993). EVALUATION OF THE COULTER STKS 5-PART DIFFERENTIAL. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 99(1), 72–81.

ENDOVASCULAR TREATMENT OF CEREBRAL ARTERIOVENOUS-MALFORMATIONS FOLLOWING RADIOSURGERY
Marks, M. P., Lane, B., Steinberg, G. K., FABRIKANT, J. I., Levy, R. P., Frankel, K. A., & Phillips, M. H. (1993). ENDOVASCULAR TREATMENT OF CEREBRAL ARTERIOVENOUS-MALFORMATIONS FOLLOWING RADIOSURGERY. AMERICAN JOURNAL OF NEURORADIOLOGY, 14(2), 297–303.

IDIOTYPE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FUSION PROTEIN AS A VACCINE FOR B-CELL LYMPHOMA
Tao, M. H., & Levy, R. (1993). IDIOTYPE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FUSION PROTEIN AS A VACCINE FOR B-CELL LYMPHOMA. NATURE, 362(6422), 755–758.

Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody
Knox, S., Hoppe, R. T., Maloney, D., Gibbs, I., Fowler, S., Marquez, C., … Levy, R. (1996). Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody. BLOOD, 87(3), 893–99.

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
Hsu, F. J., Benike, C., Fagnoni, F., Liles, T. M., Czerwinski, D., Taidi, B., … Levy, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. NATURE MEDICINE, 2(1), 52–58.

Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
Nelson, E. L., Li, X. B., Hsu, F. J., Kwak, L. W., Levy, R., CLAYBERGER, C., & KRENSKY, A. M. (1996). Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. BLOOD, 88(2), 580–89.

DNA immunization induces protective immunity against B-cell lymphoma
Syrengelas, A. D., Chen, T. T., & Levy, R. (1996). DNA immunization induces protective immunity against B-cell lymphoma. NATURE MEDICINE, 2(9), 1038–1041.

Surgical resection of large incompletely treated intracranial arteriovenous malformations following stereotactic radiosurgery
Steinberg, G. K., Chang, S. D., Levy, R. P., Marks, M. P., Frankel, K., & Marcellus, M. (1996). Surgical resection of large incompletely treated intracranial arteriovenous malformations following stereotactic radiosurgery. JOURNAL OF NEUROSURGERY, 84(6), 920–28.

A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein and DNA vaccines
Hakim, I., Levy, S., & Levy, R. (1996). A nine-amino acid peptide from IL-1 beta augments antitumor immune responses induced by protein and DNA vaccines. JOURNAL OF IMMUNOLOGY, 157(12), 5503–5511.

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial
Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., … Levy, R. (1997). Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial. BLOOD, 89(9), 3129–3135.

Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt, V. L., Okada, C. Y., Stockerl-Goldstein, K. E., Bogen, B., & Levy, R. (1997). Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biology of Blood and Marrow Transplantation , 3(3), 157–163.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
Maloney, D. G., GRILLOLOPEZ, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., … Levy, R. (1997). IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. BLOOD, 90(6), 2188–95.

IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
Maloney, D. G., GRILLOLOPEZ, A. J., Bodkin, D. J., White, C. A., Liles, T. M., Royston, I., … Levy, R. (1997). IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 15(10), 3266–3274.

Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations
Caspar, C. B., Levy, S., & Levy, R. (1997). Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations. BLOOD, 90(9), 3699–3706.

TCR vaccines for active immunotherapy of T cell malignancies
Okada, C. Y., Wong, C. P., Denney, D. W., & Levy, R. (1997). TCR vaccines for active immunotherapy of T cell malignancies. JOURNAL OF IMMUNOLOGY, 159(11), 5516–5527.

Pathological changes in surgically resected angiographically occult vascular malformations after radiation
Gewirtz, R. J., Steinberg, G. K., Crowley, R., & Levy, R. P. (1998). Pathological changes in surgically resected angiographically occult vascular malformations after radiation. NEUROSURGERY, 42(4), 738–42.

Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T. M., & Levy, R. (1998). Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. BLOOD, 92(4), 1184–90.

Stereotactic radiosurgery of angiographically occult vascular malformations: 14-year experience
Chang, S. D., Levy, R. P., Adler, J. R., Martin, D. P., Krakovitz, P. R., & Steinberg, G. K. (1998). Stereotactic radiosurgery of angiographically occult vascular malformations: 14-year experience. NEUROSURGERY, 43(2), 213–20.

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma
Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T., Liles, T. M., … Levy, R. (1996). Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. CLINICAL CANCER RESEARCH, 2(3), 457–70.

TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8(+) T cell response
Wong, C. P., Okada, C. Y., & Levy, R. (1999). TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8(+) T cell response. JOURNAL OF IMMUNOLOGY, 162(4), 2251–2258.

Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.
Alizadeh, A. A., Gentles, A. J., Plevritis, S. K., & Levy, R. (2009). Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma. BLOOD, 114(22), 1153–53.

Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Goldstein, M. J., … Levy, R. (2010). Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. BLOOD, 116(21), 836–37.

Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003
Tan, D., Rosenberg, S. A., Lavori, P., Sigal, B. M., Levy, R., Hoppe, R. T., … Horning, S. J. (2008). Closing the gap: A comparison of observed versus expected survival in follicular lymphoma (FL) at Stanford University from 1960-2003. JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system.
Yang, J. H., Kanter, G., Voloshin, A., Levy, R., & Swartz, J. (2004). Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system. Presented at the 227th National Meeting of the American-Chemical Society, ANAHEIM,CA,CA: AMER CHEMICAL SOC.

Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system.
Yang, J. H., Kanter, G., Voloshin, A., Levy, R., & Swartz, J. (2004). Rapid expression of vaccine proteins for B cell lymphoma in a cell-free system. Presented at the 227th National Meeting of the American-Chemical Society, ANAHEIM,CA,CA: AMER CHEMICAL SOC.

Cell-free synthesis enables patient-specific vaccine production.
Swartz, J. R., Levy, R., Kanter, G., Yang, J. H., & Voloshin, A. (2005). Cell-free synthesis enables patient-specific vaccine production. Presented at the 229th National Meeting of the American-Chemical-Society (ACS), SAN DIEGO,CA,CA: AMER CHEMICAL SOC.

Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma
Ng, P. P., Jia, M., Virrueta, A., Patel, K., Swartz, J. R., Levy, S., & Levy, R. (2009). Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma. BLOOD, 114(22), 1062–62.

Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts
Chao, M. P., Alizadeh, A. A., Tang, C. Z., Myklebust, J. H., Varghese, B., Jan, M., … Majeti, R. (2009). Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts. BLOOD, 114(22), 1063–64.

Expression of the human germinal center associated lymphoma (HGAL) protein identifies a subset of classical Hodgkin lymphoma of germinal center derivation and improved outcome.
Natkunam, Y., Hsi, E. D., Zhao, S. C., Elson, P., Pohlman, B., Levy, R., & Lossos, I. S. (2005). Expression of the human germinal center associated lymphoma (HGAL) protein identifies a subset of classical Hodgkin lymphoma of germinal center derivation and improved outcome. BLOOD, 106(11), 11A–12A.

RNA-binding protein VICKZ is expressed in a germinal center associated pattern among lymphoma subtypes.
Natkunam, Y., Vainer, G., Zhao, S. C., Amir, G., Pikarsky, E., Hammer, A. S., … Lossos, I. S. (2005). RNA-binding protein VICKZ is expressed in a germinal center associated pattern among lymphoma subtypes. BLOOD, 106(11), 542A–542A.

The oncoprotein LMO2 is expressed in a germinal center B-cell-associated pattern and predicts survival in patients with diffuse large B-cell lymphoma.
Natkunam, Y., Hsi, E. D., Hans, C., Zhao, S., Taidi, B., Chen, J., … Lossos, I. S. (2006). The oncoprotein LMO2 is expressed in a germinal center B-cell-associated pattern and predicts survival in patients with diffuse large B-cell lymphoma. BLOOD, 108(11), 243A–243A.

The percentage of tumor-infiltrating T cells is not correlated with overall survival in follicular B-cell lymphomas
Ai, W. Y., Czerwinski, D. K., Tibshirani, R., Horning, S. J., & Levy, R. (2004). The percentage of tumor-infiltrating T cells is not correlated with overall survival in follicular B-cell lymphomas. BLOOD, 104(11), 891A–891A.

Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation.
Natkunam, Y., Lossos, I. S., Taidi, B., Zhao, S. C., Lu, X. Q., Ding, F. Y., … Levy, R. (2004). Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation. BLOOD, 104(11), 624A–624A.

The number of CD25+tumor-infiltrating cells may predict clinical response to rituximab in follicular lymphoma patients.
Park, C. Y., Bohen, S. P., Levy, R., Warnke, R. A., & Natkunam, Y. (2004). The number of CD25+tumor-infiltrating cells may predict clinical response to rituximab in follicular lymphoma patients. BLOOD, 104(11), 214A–214A.

The T-cell oncoprotein LMO2 is expressed in normal germinal center B-cells and in germinal center-derived B-cell lymphoma
Natkunam, Y., Levy, R., Zhao, S., Taidi, B., & Lossos, I. S. (2006). The T-cell oncoprotein LMO2 is expressed in normal germinal center B-cells and in germinal center-derived B-cell lymphoma. Presented at the 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, ATLANTA,GA,GA: NATURE PUBLISHING GROUP.

Expression of the human germinal center associated lymphoma (HGAL) protein identifies a subset of classical Hodgkin lymphoma of germinal center derivation and improved outcome
Natkunam, Y., Hsi, E. D., Zhao, S., Elson, P., Pohlman, B., Levy, R., & Lossos, I. S. (2006). Expression of the human germinal center associated lymphoma (HGAL) protein identifies a subset of classical Hodgkin lymphoma of germinal center derivation and improved outcome. Presented at the 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, ATLANTA,GA,GA: NATURE PUBLISHING GROUP.

RNA-binding protein VICKZ is expressed in a germinal center associated pattern among lymphoma subtypes
Natkunam, Y., Vainer, G., Zhao, S., Amir, G., Pikarsky, E., Hammer, A. S., … Lossos, I. S. (2006). RNA-binding protein VICKZ is expressed in a germinal center associated pattern among lymphoma subtypes. Presented at the 95th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, ATLANTA,GA,GA: NATURE PUBLISHING GROUP.

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with or without rituximab
Natkunam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., … Lossos, I. S. (2008). LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with or without rituximab. Presented at the 97th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, DENVER,CO,CO: NATURE PUBLISHING GROUP.

Anti-idiotype antibody response afteir vaccination correlates with better overall survival in follicular lymphoma
Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D., & Levy, R. (2007). Anti-idiotype antibody response afteir vaccination correlates with better overall survival in follicular lymphoma. BLOOD, 110(11), 199A–199A.

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma in, the pre- and post-rituximab treatment eras
Natkumam, Y., Farinha, P., Hsi, E. D., Hans, C. P., Tibshirani, R., Sehn, L. H., … Lossos, I. S. (2007). LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma in, the pre- and post-rituximab treatment eras. BLOOD. ATLANTA,GA,GA,GA: AMER SOC HEMATOLOGY.

Survival in follicular lymphoma: The Stanford experience, 1960-2003.
Tan, D., Rosenberg, S. A., Levy, R., Lavori, P., Tibshirani, R., Hoppe, R. T., … Horning, S. J. (2007). Survival in follicular lymphoma: The Stanford experience, 1960-2003. BLOOD, 110(11), 1005A–1005A.

Major histocomplatibility class II (MHCII) and germinal center associated gene expression correlate with overall survival in ritiximab and CHOP-like treated diffuse large B.cell lymphoma (DLBCL) patients, using
Malumbres, R., Johnson, N. A., Sehn, L. H., Natkunam, Y., Tibshirani, R., Briones, J., … Lossos, I. S. (2007). Major histocomplatibility class II (MHCII) and germinal center associated gene expression correlate with overall survival in ritiximab and CHOP-like treated diffuse large B.cell lymphoma (DLBCL) patients, using. BLOOD, 110(11), 23A–23A.

T cell modulation combined with intratumoral injections of CPG oligodeoxynucleotides cures large and systemic lymphoma tumors in mice
Houot, R., Czerwinski, D. K., & Levy, R. (2008). T cell modulation combined with intratumoral injections of CPG oligodeoxynucleotides cures large and systemic lymphoma tumors in mice. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.

New immunologic treatments for lymphoma
Levy, R., Houot, R., Brody, J., & Czerwinski, D. (2008). New immunologic treatments for lymphoma. Presented at the 10th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.

CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas
Luo, R. F., Zhao, S., Tibshirani, R., Lossos, I. S., Advani, R., Gratzinger, D., … Natkunam, Y. (2009). CD81 Protein Is Expressed in Normal Germinal Center B-Cells and in Subtypes of Human Non-Hodgkin Lymphomas. Presented at the 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, BOSTON,MA,MA,MA,MA,MA,MA,MA,MA: NATURE PUBLISHING GROUP.

Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes
Irish, J. M., Houot, R., Myklebust, J. H., Czerwinski, D. K., Nolan, G. P., & Levy, R. (2008). Signaling Diversity in Human Lymphoma B Cells and in Tumor Infiltrating T Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes. BLOOD, 112(11), 146–46.

Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees.
Varghese, B., Taidi, B., Widman, A., Do, J., & Levy, R. (2008). Generation of CD8 T Cell-Mediated Protective Immunity against Tumor Escapees. BLOOD, 112(11), 908–.

Lymphoma-Expressed VEGF-a,VEGFR-1, VEGFR-2, and Microvessel Density Are Not Predictive of Overall Survival in Follicular Lymphoma.
Gratzinger, D., Zhao, S., Ai, W., Tibshirani, R., Levy, R., & Natkunam, Y. (2008). Lymphoma-Expressed VEGF-a,VEGFR-1, VEGFR-2, and Microvessel Density Are Not Predictive of Overall Survival in Follicular Lymphoma. BLOOD, 112(11), 1290–90.

A CpG-Activated Whole-Cell Vaccine 'Boost' Enhances the Anti-Lymphoma Efficacy of Immunotransplant
Brody, J., Goldstein, M. J., & Levy, R. (2008). A CpG-Activated Whole-Cell Vaccine 'Boost' Enhances the Anti-Lymphoma Efficacy of Immunotransplant. BLOOD, 112(11), 1241–41.

Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma
Gratzinger, D., Ai, W., Tibshirani, R., Levy, R., & Natkunam, Y. (2008). Neither CD68+Nor CD163+Macrophages Are Associated with Decreased Survival in Follicular Lymphoma. BLOOD, 112(11), 1284–1284.

Using Immune Response Data from a Lymphoma Vaccine Clinical Trial to Define Novel Endpoints for an Immunotransplant Trial
Brody, J., Czerwinski, D., Ai, W., & Levy, R. (2009). Using Immune Response Data from a Lymphoma Vaccine Clinical Trial to Define Novel Endpoints for an Immunotransplant Trial. Presented at the 9th Annual Meeting of the Federation-of-Clinical-Immunology-Societies, SAN FRANCISCO,CA,CA,CA,CA,CA: ACADEMIC PRESS INC ELSEVIER SCIENCE.

Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions
Alizadeh, A. A., Gentles, A. J., Alencar, A. J., Kohrt, H. E., Houot, R., Talreja, N., … Levy, R. (2009). Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions. BLOOD, 114(22), 258–58.

Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Celts to Generate Potent Anti-Tumor CD4 T Cell Immunity
Gold-Stein, M. J., Varghese, B., Rajapaksa, R., Brody, J., Levy, S., & Levy, R. (2009). Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Celts to Generate Potent Anti-Tumor CD4 T Cell Immunity. BLOOD, 114(22), 383–83.

Adoptive Therapy for Lymphoma with CD4 Memory T Cells Depleted of CD137-Expressing Tregs.
Goldstein, M. J., Houot, R., Kohrt, H. E., Brody, J., & Levy, R. (2009). Adoptive Therapy for Lymphoma with CD4 Memory T Cells Depleted of CD137-Expressing Tregs. BLOOD, 114(22), 674–75.

Therapeutic Potential of Anti-CD137 Antibody in Lymphoma
Houot, R., Goldstein, M. J., Kohrt, H. E., Myklebust, J. H., Alizadeh, A. A., Lin, J. T., … Levy, R. (2009). Therapeutic Potential of Anti-CD137 Antibody in Lymphoma. BLOOD, 114(22), 301–2.

Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular Component
Younes, S. F., Beck, A., Warnke, R. A., Lossos, I. S., Levy, R., & Natkunam, Y. (2010). Immunoarchitectural Patterns in Follicular Lymphoma: Efficacy of HGAL and LMO2 in the Detection of the Interfollicular Component. Presented at the 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology, WASHINGTON,DC,DC: NATURE PUBLISHING GROUP.

A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling
Myklebust, J. H., Irish, J. M., Houot, R., Brody, J., Czerwinski, D. K., Alizadeh, A. A., … Levy, R. (2009). A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling. BLOOD, 114(22), 316–16.

Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP)
Gratzinger, D., Advani, R., Zhao, S., Talreja, N., Tibshirani, R. J., Horning, S. J., … Natkunam, Y. (2009). Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP). JOURNAL OF CLINICAL ONCOLOGY, 27(15).

NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome
Myklebust, J. H., Irish, J. M., Brody, J., Alizadeh, A. A., Czerwinski, D., Houot, R., … Levy, R. (2010). NF-kappa B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome. BLOOD, 116(21), 67–68.

Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile
Irish, J. M., Czerwinski, D. K., Nolan, G. P., & Levy, R. (2010). Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile. BLOOD, 116(21), 279–79.

Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies
Alizadeh, A. A., Anderson, M., Kohrt, H. E., Shyam, R. M., Bangs, C. D., Cherry, A. M., … Levy, R. (2010). Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. BLOOD, 116(21), 1291–92.

CD137 Identifies a Population of Regulatory T Cells That Inhibit Anti-Tumor Immune Responses In Adoptive Immunotherapy
Goldstein, M. J., Kohrt, H. E., Houot, R., Varghese, B., Lin, J. T., Swanson, E., & Levy, R. (2010). CD137 Identifies a Population of Regulatory T Cells That Inhibit Anti-Tumor Immune Responses In Adoptive Immunotherapy. BLOOD, 116(21), 868–68.

IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS
Brody, J., Advani, R., Czerwinski, D., Negrin, R., & Levy, R. (2011). IMMUNOTRANSPLANT FOR MANTLE CELL LYMPHOMA: PHASE I/II STUDY PRELIMINARY RESULTS. Presented at the 11th International Conference on Malignant Lymphoma, LUGANO,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND,SWITZERLAND: OXFORD UNIV PRESS.

SYSTEMIC ANTITUMOR IMMUNITY TRIGGERED BY INTRATUMORAL IMMUNOMODULATION CURES DISTANT METASTATIC CNS LYMPHOMA
Marabelle, A., Kohrt, H., Brody, J., Luong, R., Tse, V., & Levy, R. (2011). SYSTEMIC ANTITUMOR IMMUNITY TRIGGERED BY INTRATUMORAL IMMUNOMODULATION CURES DISTANT METASTATIC CNS LYMPHOMA. Presented at the 16th Annual Scientific Meeting of the Society-for-Neuro-Oncology (SNO)/AANS/CNS Section on Tumors, CA: OXFORD UNIV PRESS INC.

Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results
Brody, J. D., Czerwinski, D. K., Carlton, V., Moorhead, M., Zheng, J., Klinger, M., … Levy, R. (2011). Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. BLOOD, 118(21), 1323–23.

The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms with rare exceptions
Gratzinger, D., Zhao, S., Vogel, H., Gil, E. C., Levy, R., Lossos, I., & Natkunam, Y. (2008). The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms with rare exceptions. FEDERATION AMER SOC EXP BIOL.

Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma
Green, M. R., Gentles, A. J., Nair, R. V., Irish, J. M., Levy, R., & Alizadeh, A. A. (2012). Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma. BLOOD, 120(21).

in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses
Czerwinski, D. K., Brody, J., Kohrt, H. E., Hoppe, R. T., Advani, R. H., & Levy, R. (2012). in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. BLOOD, 120(21).

Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy
Torchia, J. A., Ng, P. P., Chen, H., Kohrt, H. E., Marabelle, A., Alizadeh, A. A., & Levy, R. (2012). Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy. BLOOD, 120(21).

Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody
Houot, R., Kohrt, H., & Levy, R. (2012). Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. ONCOIMMUNOLOGY, 1(6), 957–958.

Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Scheeren, F., … Levy, R. (2012). Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Cancer vaccines: pessimism in check
Timmerman, J. M., & Levy, R. (2004). Cancer vaccines: pessimism in check. NATURE MEDICINE, 10(12), 1279–79.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
Ai, W. Z., Tibshirani, R., Taidi, B., Czerwinski, D., & Levy, R. (2009). Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. BLOOD, 113(23), 5743–5746.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Friedberg, J. W., Sharman, J., Sweetenham, J., Johnston, P. B., Vose, J. M., LaCasce, A., … Shipp, M. A. (2010). Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. BLOOD, 115(13), 2578–85.

Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Houot, R., Kohrt, H., Goldstein, M. J., & Levy, R. (2011). Immunomodulating antibodies and drugs for the treatment of hematological malignancies. CANCER AND METASTASIS REVIEWS, 30(1), 97–109.

Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma
Ai, W. Z., Kohrt, H. E. K., Timmerman, J., Hwang, J., Hsu, F. J., Czerwinski, D. D., … Levy, R. (2011). Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. AMERICAN JOURNAL OF HEMATOLOGY, 86(6), 515–18.

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
Houot, R., Kohrt, H. E., Marabelle, A., & Levy, R. (2011). Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. TRENDS IN IMMUNOLOGY, 32(11), 510–516.

CELL DYN-3000 AND COULTER STKS AUTOMATED DIFFERENTIAL COUNTERS - REPLY
Cornbleet, P. J., Myrick, D., Levy, R., & JUDKINS, S. (1993). CELL DYN-3000 AND COULTER STKS AUTOMATED DIFFERENTIAL COUNTERS - REPLY. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 100(4), 464–465.

STANFORD STUDY OF SEZARY SYNDROME
Rich, L., Levy, R., Horning, S., & Merigan, T. C. (1983). STANFORD STUDY OF SEZARY SYNDROME. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 9(2), 279–279.

Multiple BCL6 translocation partners in individual cases of gastric lymphoma - Response
Lossos, I. S., Akasaka, T., & Levy, R. (2003). Multiple BCL6 translocation partners in individual cases of gastric lymphoma - Response. BLOOD, 102(5), 1932–1932.

SYNGENEIC ANTIIDIOTYPIC IMMUNE-RESPONSES TO A B-CELL LYMPHOMA - COMPARISON BETWEEN HEAVY-CHAIN HYPERVARIABLE REGION PEPTIDES AND INTACT IG AS IMMUNOGENS
Thielemans, K., Rothbard, J. B., Levy, S., & Levy, R. (1985). SYNGENEIC ANTIIDIOTYPIC IMMUNE-RESPONSES TO A B-CELL LYMPHOMA - COMPARISON BETWEEN HEAVY-CHAIN HYPERVARIABLE REGION PEPTIDES AND INTACT IG AS IMMUNOGENS. JOURNAL OF EXPERIMENTAL MEDICINE, 162(1), 19–34.

Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions
Lossos, I. S., & Levy, R. (2003). Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. SEMINARS IN CANCER BIOLOGY, 13(3), 191–202.

TREATMENT OF A MURINE B-CELL LYMPHOMA WITH MONOCLONAL-ANTIBODIES AND IL-2
Berinstein, N., & Levy, R. (1987). TREATMENT OF A MURINE B-CELL LYMPHOMA WITH MONOCLONAL-ANTIBODIES AND IL-2. JOURNAL OF IMMUNOLOGY, 139(3), 971–976.

Diffuse large B-cell lymphoma: Insights gained from gene expression profiling
Lossos, I. S., & Levy, R. (2003). Diffuse large B-cell lymphoma: Insights gained from gene expression profiling. INTERNATIONAL JOURNAL OF HEMATOLOGY, 77(4), 321–329.

TRANSFORMATION OF MYCOSIS-FUNGOIDES - T-CELL RECEPTOR-BETA GENE ANALYSIS DEMONSTRATES A COMMON CLONAL ORIGIN FOR PLAQUE-TYPE MYCOSIS-FUNGOIDES AND CD30+ LARGE-CELL LYMPHOMA
Wood, G. S., Bahler, D. W., Hoppe, R. T., Warnke, R. A., Sklar, J. L., & Levy, R. (1993). TRANSFORMATION OF MYCOSIS-FUNGOIDES - T-CELL RECEPTOR-BETA GENE ANALYSIS DEMONSTRATES A COMMON CLONAL ORIGIN FOR PLAQUE-TYPE MYCOSIS-FUNGOIDES AND CD30+ LARGE-CELL LYMPHOMA. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 101(3), 296–300.

Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas.
Renschler, M. F., Dower, W. J., & Levy, R. (1998). Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas. Methods in Molecular Biology (Clifton, N.J.), 87, 209–234.

BICLONAL B-CELL LYMPHOMA
Sklar, J., Cleary, M. L., Thielemans, K., Gralow, J., Warnke, R., & Levy, R. (1984). BICLONAL B-CELL LYMPHOMA. NEW ENGLAND JOURNAL OF MEDICINE, 311(1), 20–27.

A SUBMICROSCOPIC INTERSTITIAL DELETION OF CHROMOSOME-14 FREQUENTLY OCCURS ADJACENT TO THE T(14 18) TRANSLOCATION BREAKPOINT IN HUMAN FOLLICULAR LYMPHOMA
Zelenetz, A. D., Cleary, M. L., & Levy, R. (1993). A SUBMICROSCOPIC INTERSTITIAL DELETION OF CHROMOSOME-14 FREQUENTLY OCCURS ADJACENT TO THE T(14 18) TRANSLOCATION BREAKPOINT IN HUMAN FOLLICULAR LYMPHOMA. GENES CHROMOSOMES & CANCER, 6(3), 140–150.

STUDIES OF A HUMAN LYMPHOCYTE-T ANTIGEN RECOGNIZED BY A MONOCLONAL-ANTIBODY
Engleman, E. G., Warnke, R., FOX, R. I., Dilley, J., Benike, C. J., & Levy, R. (1981). STUDIES OF A HUMAN LYMPHOCYTE-T ANTIGEN RECOGNIZED BY A MONOCLONAL-ANTIBODY. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 78(3), 1791–1795.

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
Tan, D., Horning, S. J., Hoppe, R. T., Levy, R., Rosenberg, S. A., Sigal, B. M., … Advani, R. H. (2013). Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 122(6), 981–87.

EFFECTS OF INTERFERON ON PATIENTS WITH NON-HODGKINS LYMPHOMA
Sikora, K., Levy, R., Merigan, T., & Rosenberg, S. (1979). EFFECTS OF INTERFERON ON PATIENTS WITH NON-HODGKINS LYMPHOMA. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 20(MAR), 299–99.

(90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma
Davis, T. A., Goris, M. L., Trisler, K. D., Negrin, R., Liles, T. M., Fowler, S. F., … Knox, S. (1995). (90)Yttrium labeled anti-CD20 therapy for recurrent B cell lymphoma. BLOOD, 86(10), 1080–80.

CLUSTERING OF EXTENSIVE SOMATIC MUTATIONS IN THE VARIABLE REGION OF AN IMMUNOGLOBULIN HEAVY-CHAIN GENE FROM A HUMAN B-CELL LYMPHOMA
Cleary, M. L., MEEKER, T. C., Levy, S., Lee, E., Trela, M., Sklar, J., & Levy, R. (1986). CLUSTERING OF EXTENSIVE SOMATIC MUTATIONS IN THE VARIABLE REGION OF AN IMMUNOGLOBULIN HEAVY-CHAIN GENE FROM A HUMAN B-CELL LYMPHOMA. CELL, 44(1), 97–106.

STRATEGIES FOR PRODUCTION OF MONOCLONAL ANTI-IDIOTYPE ANTIBODIES AGAINST HUMAN B-CELL LYMPHOMAS
Thielemans, K., Maloney, D. G., Meeker, T., Fujimoto, J., Doss, C., Warnke, R. A., … Levy, R. (1984). STRATEGIES FOR PRODUCTION OF MONOCLONAL ANTI-IDIOTYPE ANTIBODIES AGAINST HUMAN B-CELL LYMPHOMAS. JOURNAL OF IMMUNOLOGY, 133(1), 495–501.

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a
Davis, T. A., Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Williams, M. E., Weiner, G. J., … Levy, R. (2000). Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. CLINICAL CANCER RESEARCH, 6(7), 2644–2652.

Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity.
Marabelle, A., Kohrt, H., & Levy, R. (2013). Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clinical Cancer Research , 19(19), 5261–63.

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
Marabelle, A., Kohrt, H., & Levy, R. (2013). Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity. CLINICAL CANCER RESEARCH, 19(19), 5261–5263.

MOUSE X HUMAN HETEROHYBRIDOMAS AS FUSION PARTNERS WITH HUMAN B-CELL TUMORS
Carroll, W. L., Thielemans, K., Dilley, J., & Levy, R. (1986). MOUSE X HUMAN HETEROHYBRIDOMAS AS FUSION PARTNERS WITH HUMAN B-CELL TUMORS. JOURNAL OF IMMUNOLOGICAL METHODS, 89(1), 61–72.

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., … André, P. (2014). Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood, 123(5), 678–86.

B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins.
Ng, P. P., Kuo, C.-C., Wang, S., Einav, S., Arcaini, L., Paulli, M., … Levy, S. (2014). B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood, 123(10), 1512–15.

INVITRO TESTS THAT PREDICT TUMOR-ASSOCIATED IDIOTYPE LEVELS IN THE SERUM OF PATIENTS WITH B-CELL LYMPHOMAS AND LEUKEMIAS
MILLER, R. A., Lowder, J. N., Gralow, J., Meeker, T., & Levy, R. (1987). INVITRO TESTS THAT PREDICT TUMOR-ASSOCIATED IDIOTYPE LEVELS IN THE SERUM OF PATIENTS WITH B-CELL LYMPHOMAS AND LEUKEMIAS. BLOOD, 69(4), 1249–1254.

HUMAN THYMUS-LEUKEMIA ANTIGEN DEFINED BY HYBRIDOMA MONOCLONAL-ANTIBODIES
Levy, R., Dilley, J., FOX, R. I., & Warnke, R. (1979). HUMAN THYMUS-LEUKEMIA ANTIGEN DEFINED BY HYBRIDOMA MONOCLONAL-ANTIBODIES. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 76(12), 6552–6556.

THE IMMUNOLOGICAL CHARACTERIZATION OF 95 NODAL AND EXTRANODAL DIFFUSE LARGE CELL LYMPHOMAS IN 89 PATIENTS
Doggett, R. S., Wood, G. S., Horning, S., Levy, R., Dorfman, R. F., Bindl, J., & Warnke, R. A. (1984). THE IMMUNOLOGICAL CHARACTERIZATION OF 95 NODAL AND EXTRANODAL DIFFUSE LARGE CELL LYMPHOMAS IN 89 PATIENTS. AMERICAN JOURNAL OF PATHOLOGY, 115(2), 245–252.

CLONAL EXPANSION IN FOLLICULAR LYMPHOMA OCCURS SUBSEQUENT TO ANTIGENIC SELECTION
Zelenetz, A. D., Chen, T. T., & Levy, R. (1992). CLONAL EXPANSION IN FOLLICULAR LYMPHOMA OCCURS SUBSEQUENT TO ANTIGENIC SELECTION. JOURNAL OF EXPERIMENTAL MEDICINE, 176(4), 1137–48.

A CLINICAL-TRIAL OF ANTI-IDIOTYPE THERAPY FOR B-CELL MALIGNANCY
MEEKER, T. C., Lowder, J., Maloney, D. G., MILLER, R. A., Thielemans, K., Warnke, R., & Levy, R. (1985). A CLINICAL-TRIAL OF ANTI-IDIOTYPE THERAPY FOR B-CELL MALIGNANCY. BLOOD, 65(6), 1349–1363.

DIFFERENCES IN HOST INFILTRATES AMONG LYMPHOMA PATIENTS TREATED WITH ANTI-IDIOTYPE ANTIBODIES - CORRELATION WITH TREATMENT RESPONSE
Garcia, C. F., Lowder, J., MEEKER, T. C., Bindl, J., Levy, R., & Warnke, R. A. (1985). DIFFERENCES IN HOST INFILTRATES AMONG LYMPHOMA PATIENTS TREATED WITH ANTI-IDIOTYPE ANTIBODIES - CORRELATION WITH TREATMENT RESPONSE. JOURNAL OF IMMUNOLOGY, 135(6), 4252–4260.

The immunobiology of B cell lymphoma: clonal heterogeneity as revealed by anti-idiotype antibodies and immunoglobulin gene probes.
Levy, R., Meeker, T., Lowder, J., Levy, S., Thielemans, K., Warnke, R. A., … Sklar, J. (1986). The immunobiology of B cell lymphoma: clonal heterogeneity as revealed by anti-idiotype antibodies and immunoglobulin gene probes. Symposium on Fundamental Cancer Research, 38, 261–268.

Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res., 60: 2335-2341, 2000.
Lossos, I. S., Jacobs, Y., Cleary, M. L., & Levy, R. (2001). Re: Akasaka, H., et al., Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res., 60: 2335-2341, 2000. Cancer Research, 61(19), 7363–7364.

DETECTION OF B-CELL LYMPHOMA IN PERIPHERAL-BLOOD BY DNA HYBRIDIZATION
Hu, E., Thompson, J., Horning, S., Trela, M., Lowder, J., Levy, R., & Sklar, J. (1985). DETECTION OF B-CELL LYMPHOMA IN PERIPHERAL-BLOOD BY DNA HYBRIDIZATION. LANCET, 2(8464), 1092–1095.

CLINICAL RELEVANCE OF IMMUNOLOGICAL PHENOTYPE IN DIFFUSE LARGE CELL LYMPHOMA
Horning, S. J., Doggett, R. S., Warnke, R. A., Dorfman, R. F., Cox, R. S., & Levy, R. (1984). CLINICAL RELEVANCE OF IMMUNOLOGICAL PHENOTYPE IN DIFFUSE LARGE CELL LYMPHOMA. BLOOD, 63(5), 1209–15.

EMERGENCE OF IDIOTYPE VARIANTS DURING TREATMENT OF B-CELL LYMPHOMA WITH ANTI-IDIOTYPE ANTIBODIES
Meeker, T., Lowder, J., Cleary, M. L., Stewart, S., Warnke, R., Sklar, J., & Levy, R. (1985). EMERGENCE OF IDIOTYPE VARIANTS DURING TREATMENT OF B-CELL LYMPHOMA WITH ANTI-IDIOTYPE ANTIBODIES. NEW ENGLAND JOURNAL OF MEDICINE, 312(26), 1658–1665.

MONOCLONAL-ANTIBODY THERAPY OF LYMPHOID MALIGNANCY
Lowder, J. N., MEEKER, T. C., & Levy, R. (1985). MONOCLONAL-ANTIBODY THERAPY OF LYMPHOID MALIGNANCY. CANCER SURVEYS, 4(2), 359–375.

STUDIES ON B-LYMPHOID TUMORS TREATED WITH MONOCLONAL ANTIIDIOTYPE ANTIBODIES - CORRELATION WITH CLINICAL-RESPONSES
Lowder, J. N., MEEKER, T. C., Campbell, M., Garcia, C. F., Gralow, J., MILLER, R. A., … Levy, R. (1987). STUDIES ON B-LYMPHOID TUMORS TREATED WITH MONOCLONAL ANTIIDIOTYPE ANTIBODIES - CORRELATION WITH CLINICAL-RESPONSES. BLOOD, 69(1), 199–210.

Intratumoral immunization: a new paradigm for cancer therapy.
Marabelle, A., Kohrt, H., Caux, C., & Levy, R. (2014). Intratumoral immunization: a new paradigm for cancer therapy. Clinical Cancer Research , 20(7), 1747–56.

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.
Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E. M., Butchar, J. P., Cheney, C., … Byrd, J. C. (2014). Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood, 123(12), 1957–60.

A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….
Levy, R. (2014). A brief personal history of cancer immunotherapy at Stanford: if these walls could talk…. Immunologic Research, 58(2-3), 277–81.

Targeting CD137 enhances the efficacy of cetuximab.
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., … Levy, R. (2014). Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 124(6), 2668–82.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., … Denney, D. W. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology , 32(17), 1797–1803.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., … Denney, D. W. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of Clinical Oncology , 32(17), 1797–1803.

Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma.
Lim, S. H., & Levy, R. (2014). Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma. Journal of Immunology , 193(4), 1519–24.

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., … Alizadeh, A. A. (2015). Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 112(10), E1116–25.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015). Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proceedings of the National Academy of Sciences of the United States of America, 112(9), E966–72.

Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Sagiv-Barfi, I., Kohrt, H. E., Burckhardt, L., Czerwinski, D. K., & Levy, R. (2015). Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood, 125(13), 2079–86.

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
Kurtz, D. M., Green, M. R., Bratman, S. V., Scherer, F., Liu, C. L., Kunder, C. A., … Alizadeh, A. A. (2015). Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 125(24), 3679–87.

Joint Modeling and Registration of Cell Populations in Cohorts of High-Dimensional Flow Cytometric Data
Pyne, S., Lee, S. X., Wang, K., Irish, J., Tamayo, P., Nazaire, M.-D., … McLachlan, G. J. (2014). Joint Modeling and Registration of Cell Populations in Cohorts of High-Dimensional Flow Cytometric Data. PLOS ONE, 9(7).

Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
Crittenden, M., Kohrt, H., Levy, R., Jones, J., Camphausen, K., Dicker, A., … Formenti, S. (2015). Current Clinical Trials Testing Combinations of Immunotherapy and Radiation. SEMINARS IN RADIATION ONCOLOGY, 25(1), 54–64.

Enhancement of antibody fragment secretion into the Escherichia coli periplasm by co-expression with the peptidyl prolyl isomerase, FkpA, in the cytoplasm
Levy, R., Ahluwalia, K., Bohmann, D. J., Giang, H. M., Schwimmer, L. J., Issafras, H., … Takeuchi, T. (2013). Enhancement of antibody fragment secretion into the Escherichia coli periplasm by co-expression with the peptidyl prolyl isomerase, FkpA, in the cytoplasm. JOURNAL OF IMMUNOLOGICAL METHODS, 394(1-2), 10–21.

Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.
Green, M. R., Kihira, S., Liu, C. L., Nair, R. V., Salari, R., Gentles, A. J., … Alizadeh, A. A. (2015). Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 112(10), E1116–25.

Tetraspanin CD81 Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory and Myeloid-Derived Suppressor Cells
Vences-Catalan, F., Rajapaksa, R., Srivastava, M. K., Marabelle, A., Kuo, C.-C., Levy, R., & Levy, S. (2015). Tetraspanin CD81 Promotes Tumor Growth and Metastasis by Modulating the Functions of T Regulatory and Myeloid-Derived Suppressor Cells. CANCER RESEARCH, 75(21), 4517–26.

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015). Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proceedings of the National Academy of Sciences of the United States of America, 112(9), E966–72.

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P. R., Janakiraman, N., … Bender, J. F. (2006). Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. JOURNAL OF CLINICAL ONCOLOGY, 24(19), 3107–12.

Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies
Torchia, J., Weiskopf, K., & Levy, R. (2016). Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 113(19), 5376–81.

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2016). Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. SCIENCE TRANSLATIONAL MEDICINE, 8(364).

Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop
Houot, R., Gaulard, P., Schreiber, R., Mellman, I., Lambotte, O., Coulie, P. G., … Olive, D. (2016). Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. ONCOIMMUNOLOGY, 5(7).

Results From an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D. F., Melero, I., Hamid, O., … Levy, R. (2016). Results From an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research .

Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., … Alizadeh, A. A. (2017). Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. NATURE, 543(7647), 723-?

Anti-DNA antibody/cationic lipid micelles for plasmid DNA gene delivery
Song, C. X., Wang, M. Y., Yang, J., Jin, X., Mei, L., Leng, X. G., … Levy, R. J. (2005). Anti-DNA antibody/cationic lipid micelles for plasmid DNA gene delivery. ASBM6: ADVANCED BIOMATERIALS VI, 288-289, 105–8.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust, J. H., Brody, J., Kohrt, H. E., Kolstad, A., Czerwinski, D. K., Wälchli, S., … Levy, R. (2017). Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood, 129(6), 759–70.

CD81 as a tumor target.
Vences-Catalán, F., Duault, C., Kuo, C.-C., Rajapaksa, R., Levy, R., & Levy, S. (2017). CD81 as a tumor target. Biochemical Society Transactions, 45(2), 531–35.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., … Levy, R. (2017). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. CLINICAL CANCER RESEARCH, 23(8), 1929–36.

Epstein-Barr virus-positive follicular lymphoma
Mackrides, N., Campuzano-Zuluaga, G., Maque-Acosta, Y., Moul, A., Hijazi, N., Ikpatt, F. O., … Chapman, J. (2017). Epstein-Barr virus-positive follicular lymphoma. MODERN PATHOLOGY, 30(4), 519–29.

Epstein-Barr virus-positive follicular lymphoma.
Mackrides, N., Campuzano-Zuluaga, G., Maque-Acosta, Y., Moul, A., Hijazi, N., Ikpatt, F. O., … Chapman, J. (2017). Epstein-Barr virus-positive follicular lymphoma. Modern Pathology , 30(4), 519–29.

Eradication of spontaneous malignancy by local immunotherapy.
Sagiv-Barfi, I., Czerwinski, D., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018). Eradication of spontaneous malignancy by local immunotherapy. . SCIENCE TRANSLATIONAL MEDICINE, 10(426).

T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins.
Olsson, N., Schultz, L. M., Zhang, L., Khodadoust, M. S., Narayan, R., Czerwinski, D. K., … Elias, J. E. (2018). T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins. Proteomics.

Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.
Kooreman, N. G., Kim, Y., de Almeida, P. E., Termglinchan, V., Diecke, S., Shao, N.-Y. Y., … Wu, J. C. (2018). Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. Cell Stem Cell.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
Boyiadzis, M., Bishop, M. R., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., … Dhodapkar, M. V. (2016). The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 4, 90.

A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients
Gentles, A., Alizadeh, A., Lee, S.-I., Shahbaba, B., Shachaf, C., Levy, R., … Plevritis, S. (2009). A stem cell-like signature predicts histological transformation and influences survival in follicular lymphoma patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M., Lund, P., Lira, R. R., … Levy, R. (2013). Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses
Sagiv-Barfi, I., Lu, H., Hewitt, J., Hsu, F. J., ter Meulen, J., & Levy, R. (2015). Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses. BLOOD, 126(23).

Generating Chimeric Antigen Receptors Utilizing Novel Anti-CD3 Nanobeads
Schultz, L. M., Czerwinski, D. K., Fu, A., Levy, S., & Levy, R. (2014). Generating Chimeric Antigen Receptors Utilizing Novel Anti-CD3 Nanobeads. BLOOD, 124(21).

Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Chester, C., Chang, S., Kurland, J. F., Sagiv-Barfi, I., Czerwinski, D., Rajapaksa, A., … Kohrt, H. E. (2014). Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma
Knox, S. J., & Levy, R. (2015). CCR 20th Anniversary Commentary: Radioactive Drones for B-cell Lymphoma. CLINICAL CANCER RESEARCH, 21(3), 493–94.

Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013)
Rezvani, K., Brody, J. D., Kohrt, H. E., Logan, A. C., Advani, R., Czerwinski, D. K., … Barrett, J. (2013). Cancer Vaccines and T Cell Therapy (vol 19, pg S97, 2013). BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(10), 1530.

New insights into the mechanism of action of immune checkpoint antibodies
Marabelle, A., Kohrt, H., & Levy, R. (2014). New insights into the mechanism of action of immune checkpoint antibodies. ONCOIMMUNOLOGY, 3(8).

A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL)
Melero, I., Gangadhar, T. C., Kohrt, H. E., Segal, N. H., Logan, T., Urba, W. J., … Goldberg, S. M. (2013). A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). JOURNAL OF CLINICAL ONCOLOGY, 31(15).

T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Josefsson, S. E., Huse, K., Kolstad, A., Beiske, K., Pende, D., Steen, C. B., … Myklebust, J. H. (2018). T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. CLINICAL CANCER RESEARCH, 24(4), 870–81.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., … Go, W. Y. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. NEW ENGLAND JOURNAL OF MEDICINE, 377(26), 2531–44.

Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., … Levy, R. (2015). Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis. BLOOD. AMER SOC HEMATOLOGY.

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)
Scherer, F., Kurtz, D. M., Green, M. R., Newman, A. M., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). JOURNAL OF CLINICAL ONCOLOGY, 33(15).

A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+NHL.
Gopal, A. K., Bartlett, N. L., Levy, R., Houot, R., Smith, S. D., Segal, N. H., … Kohrt, H. E. (2015). A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+NHL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis
Vences-Catalan, F., Rajapaksa, R., Srivastava, M. K., Marabelle, A., Kuo, C.-C., Levy, R., & Levy, S. (2016). Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. ONCOIMMUNOLOGY, 5(5), e1120399.

Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Liu, C. L., Zhou, L., … Alizadeh, A. A. (2015). Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.
Kurtz, D. M., Green, M. R., Bratman, S. V., Liu, C.-L., Glover, C., Keane, C., … Alizadeh, A. A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Local immunomodulation at a single site of tumor generates a therapeutic immune response that cures metastatic disease at distant sites, including the brain.
Marabelle, A., Kohrt, H., & Levy, R. (2013). Local immunomodulation at a single site of tumor generates a therapeutic immune response that cures metastatic disease at distant sites, including the brain. CANCER RESEARCH, 73.

Monoclonal antibodies and in situ vaccination.
Levy, R. (2015). Monoclonal antibodies and in situ vaccination. CLINICAL CANCER RESEARCH, 21.

A roadmap for discovery and translation in lymphoma
Weinstock, D. M., Dalla-Favera, R., Gascoyne, R. D., Leonard, J. P., Levy, R., Lossos, I. S., … Staudt, L. M. (2015). A roadmap for discovery and translation in lymphoma. BLOOD, 125(13), 2175–77.

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Segal, N. H., He, A. R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M. J., … Gopal, A. K. (2018). Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. CLINICAL CANCER RESEARCH, 24(8), 1816–23.

Combining Ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors
Sagiv-Barfi, I., Kohrt, H., Czerwinski, D., Ng, P., Chang, B., & Levy, R. (2015). Combining Ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors. CANCER RESEARCH, 75.

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Chu, M. P., Okada, A., … Levy, R. (2015). Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. BLOOD. AMER SOC HEMATOLOGY.

In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease
Marabelle, A., Kohrt, H., Brody, J., Torchia, J., Rajapaksa, R., Luong, R., … Levy, R. (2012). In situ Treg immunomodulation at a single tumor site with CpG and immune checkpoint antibodies cures metastatic disease. CANCER RESEARCH, 72.

Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.
Khodadoust, M. S., Chu, M. P., Czerwinski, D., McDonald, K., Long, S., Kohrt, H. E., … Levy, R. (2015). Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipillumumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.
Kurtz, D. M., Scherer, F., Green, M. R., Khodadoust, M. S., Klass, D. M., Zhou, L., … Alizadeh, A. A. (2015). Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Local tumor irradiation combined with alpha-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series
Sagiv-Barfi, I., Rajapaksa, A., Czerwinski, D., Chang, S., Hebb, J., Chester, C., … Kohrt, H. (2014). Local tumor irradiation combined with alpha-PDL-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies
Kohrt, H. E., Godwin, J. E., Lossos, I. S., Williams, M. E., Timmerman, J., Link, B. K., … Levy, R. (2013). A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

A phase 1 study of PF-05082566 (auti-4-1BB) in patients with advanced cancer.
Segal, N. H., Gopal, A. K., Bhatia, S., Kohrt, H. E., Levy, R., Pishvalan, M. J., … Davis, C. (2014). A phase 1 study of PF-05082566 (auti-4-1BB) in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC
Schultz, L. M., Olsson, N., Khodadoust, M., Narayan, R., Sagiv-Barfi, I., Elias, J., & Levy, R. (2015). T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC. BLOOD. AMER SOC HEMATOLOGY.

Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy
Chan, W., Theriault, T., Levy, R., & Swartz, J. (2015). Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy. BLOOD, 126(23).

First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.
Brownstein, C. M., Adriaens, L., Bannerji, R., Chavez, J. C., Levy, R., Ansell, S. M., … Kohrt, H. E. (2015). First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy. JOURNAL OF CLINICAL ONCOLOGY, 33(15).

An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.
Salles, G. A., Gopal, A. K., Martin, P., Marcus, R., Hess, G., Zinzani, P. L., … Levy, R. (2013). An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 31(15).

Semi-synthetic peptibodies are a novel personalized therapeutic with activity against lymphoma in vitro and in vivo
Torchia, J., Ng, P., Chen, H., Weiskopf, K., & Levy, R. (2014). Semi-synthetic peptibodies are a novel personalized therapeutic with activity against lymphoma in vitro and in vivo. CANCER RESEARCH, 74(19).

Imaging activated T cells predicts response to cancer vaccines.
Alam, I. S., Mayer, A. T., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., … Gambhir, S. S. (2018). Imaging activated T cells predicts response to cancer vaccines. The Journal of Clinical Investigation.

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018785246.

In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.
Frank, M. J., Reagan, P. M., Bartlett, N. L., Gordon, L. I., Friedberg, J. W., Czerwinski, D. K., … Levy, R. (2018). In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery.

mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.
Haabeth, O. A., Blake, T. R., McKinlay, C. J., Waymouth, R. M., Wender, P. A., & Levy, R. (2018). mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proceedings of the National Academy of Sciences of the United States of America.

Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.
Sallets, A., Robinson, S., Kardosh, A., & Levy, R. (2018). Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. Blood Advances, 2(17), 2230–41.

Circulating tumor DNA (ctDNA) in B-cell lymphoma
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., … Alizadeh, A. A. (2018). Circulating tumor DNA (ctDNA) in B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. WILEY.

B cell lymphomas present immunoglobulin neoantigens.
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C. L., … Alizadeh, A. A. (2018). B cell lymphomas present immunoglobulin neoantigens. Blood.

Single-cell RNA-Seq of lymphoma cancers reveals malignant B cell types and co-expression of T cell immune checkpoints.
Andor, N., Simonds, E. F., Czerwinski, D. K., Chen, J., Grimes, S. M., Wood-Bouwens, C., … Ji, H. P. (2018). Single-cell RNA-Seq of lymphoma cancers reveals malignant B cell types and co-expression of T cell immune checkpoints. Blood.

TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma.
Josefsson, S. E., Beiske, K., Blaker, Y. N., Forsund, M. S., Holte, H., Ostenstad, B., … Myklebust, J. H. (2019). TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma. Cancer Immunology Research.

Local delivery of OX40L, CD80, and CD86 mRNA kindles global anti-cancer immunity.
Haabeth, O. A., Blake, T. R., McKinlay, C. J., Tveita, A. A., Sallets, A., Waymouth, R. M., … Levy, R. (2019). Local delivery of OX40L, CD80, and CD86 mRNA kindles global anti-cancer immunity. Cancer Research.

Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial
Shree, T., Sathe, A., Czerwinski, D. K., Long, S. R., Ji, H., & Levy, R. (2018). Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial. BLOOD, 132.

Eradication of spontaneous malignancy by local immunotherapy.
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018). Eradication of spontaneous malignancy by local immunotherapy. Science Translational Medicine, 10(426).

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
Turaj, A. H., Cox, K. L., Penfold, C. A., French, R. R., Mockridge, C. I., Willoughby, J. E., … Lim, S. H. (2018). Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Scientific Reports, 8(1), 2278.

New insights into the mechanism of action of immune checkpoint antibodies.
Marabelle, A., Kohrt, H., & Levy, R. (2014). New insights into the mechanism of action of immune checkpoint antibodies. Oncoimmunology, 3(8), e954869.

Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity
Haabeth, O. A. W., Blake, T. R., McKinlay, C. J., Tveita, A. A., Sallets, A., Waymouth, R. M., … Levy, R. (2019). Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity. CANCER RESEARCH, 79(7), 1624–34.

CD81 is a novel immunotherapeutic target for B cell lymphoma.
Vences-Catalan, F., Kuo, C.-C., Rajapaksa, R., Duault, C., Andor, N., Czerwinski, D. K., … Levy, S. (2019). CD81 is a novel immunotherapeutic target for B cell lymphoma. The Journal of Experimental Medicine.

Positron emission tomography imaging of activated T cells by targeting OX40 reveals spatiotemporal immune dynamics and predicts response to in situ tumor vaccination
Mayer, A. T., Alam, I. S., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., … Gambhir, S. S. (2018). Positron emission tomography imaging of activated T cells by targeting OX40 reveals spatiotemporal immune dynamics and predicts response to in situ tumor vaccination. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy
Mooney, K., Long, S., Martin, B., Frank, M., Czerwinski, D., Levy, R., … Greenstein, R. (2019). Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.

Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy
Mooney, K., Long, S., Martin, B., Frank, M., Czerwinski, D., Levy, R., … Greenstein, R. (2019). Serial Fine Needle Aspiration (FNA) Allows Direct Sampling of Low-grade Lymphoma Tumor Nodules and Subsequent Analysis of the Tumor and Its Microenvironment in Clinical Trial Patients Receiving Immunotherapy. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.

Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints
Andor, N., Simonds, E. F., Czerwinski, D. K., Chen, J., Grimes, S. M., Wood-Bouwens, C., … Ji, H. P. (2019). Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. BLOOD, 133(10), 1119–29.

Predicting HLA class II antigen presentation through integrated deep learning.
Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., … Alizadeh, A. A. (2019). Predicting HLA class II antigen presentation through integrated deep learning. Nature Biotechnology.

Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma
Shree, T., Khodadoust, M. S., Czerwinski, D., Frank, M. J., Hong, W. X., Greenstein, R., … Levy, R. (2019). Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoing in situ vaccination
Shree, T., Sathe, A., Ji, H., & Levy, R. (2019). Single cell RNA sequencing of serial tumor and blood biopsies from lymphoma patients undergoing in situ vaccination. CANCER RESEARCH, 79(13).

Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Timmerman, J., Herbaux, C., Ribrag, V., Zelenetz, A. D., Houot, R., Neelapu, S. S., … Levy, R. (2020). Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. American Journal of Hematology.

Intratumoral immunotherapy for early stage solid tumors.
Hong, W. X., Haebe, S., Lee, A., Westphalen, B., Norton, J. A., Jiang, W., & Levy, R. (2020). Intratumoral immunotherapy for early stage solid tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.
Shree, T., Li, Q., Glaser, S. L., Brunson, A., Maecker, H. T., Haile, R. W., … Keegan, T. H. (2020). Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1901937.

First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas.
Gopal, A. K., Levy, R., Houot, R., Patel, S. P., Popplewell, L., Jacobson, C., … Bartlett, N. L. (2020). First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., … Levy, R. (2020). Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of Experimental Medicine, 217(9).

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
Houot, R., Levy, R., Cartron, G., & Armand, P. (2020). Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? European Journal of Cancer (Oxford, England : 1990), 136, 4–6.

Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy.
Wilk, A. J., Weidenbacher, N. L.-B., Vergara, R., Haabeth, O. A., Levy, R., Waymouth, R. M., … Blish, C. A. (2020). Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Advances, 4(17), 4244–55.

Neoadjuvant Immunotherapy for Solid Tumors
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D., & Levy, R. (2020). Neoadjuvant Immunotherapy for Solid Tumors. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 231(4), S275.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., … Bishop, M. R. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. Journal for Immunotherapy of Cancer, 8(2).

Neoadjuvant immunotherapy for solid tumors
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D., & Levy, R. (2020). Neoadjuvant immunotherapy for solid tumors. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma.
Haebe, S. E., Shree, T., Sathe, A., Day, G., Czerwinski, D. K., Grimes, S., … Levy, R. (2021). Single Cell Analysis Can Define Distinct Evolution of Tumor Sites in Follicular Lymphoma. Blood.

Targeting the tetraspanin CD81 reduces cancer invasion and metastasis.
Vences-Catalán, F., Rajapaksa, R., Kuo, C.-C. C., Miller, C. L., Lee, A., Ramani, V. C., … Levy, S. (2021). Targeting the tetraspanin CD81 reduces cancer invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 118(24).

An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.
Haabeth, O. A., Lohmeyer, J. J., Sallets, A., Blake, T. R., Sagiv-Barfi, I., Czerwinski, D. K., … Levy, R. (2021). An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. ACS Central Science, 7(7), 1191–1204.

Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy.
Mooney, K. L., Czerwinski, D. K., Shree, T., Frank, M. J., Haebe, S., Martin, B. A., … Long, S. R. (2021). Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathology.

Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression.
Miller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Artandi, S. E., Bertozzi, C. R., … Cochran, J. R. (2021). Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. Cell Chemical Biology.

How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies.
Ribas, A., Dhodapkar, M. V., Campbell, K. M., Davies, F. E., Gore, S. D., Levy, R., & Greenberger, L. M. (2021). How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. Blood Cancer Discovery, 2(6), 562–567.

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., … Levy, R. (2022). CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity. Blood Cancer Discovery.

CD81 costimulation skews CAR transduction toward naive T cells.
Schultz, L. M., Czerwinski, D. K., Levy, R., & Levy, S. (1800). CD81 costimulation skews CAR transduction toward naive T cells. Proceedings of the National Academy of Sciences of the United States of America, 119(5).

Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2022). Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Research.

SYSTEMIC DELIVERY OF A TUMOR-TARGETED TLR9 AGONIST CONJUGATE TRANSFORMS THE TUMOR IMMUNE LANDSCAPE AND INDUCES TUMOR REGRESSION IN MICE
Candidate, C. M., Sagiv-Barfi, I., Neuhoefer, P., Czerwinski, D., Artandi, S., Bertozzi, C., … Cochran, J. (2021). SYSTEMIC DELIVERY OF A TUMOR-TARGETED TLR9 AGONIST CONJUGATE TRANSFORMS THE TUMOR IMMUNE LANDSCAPE AND INDUCES TUMOR REGRESSION IN MICE. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.

Intratumoral immunotherapy relies on B and T cell collaboration.
Sagiv-Barfi, I., Czerwinski, D. K., Shree, T., Lohmeyer, J. J., & Levy, R. (2022). Intratumoral immunotherapy relies on B and T cell collaboration. Science Immunology, 7(71), eabn5859.

Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro.
Testa, S., Haabeth, O. A., Blake, T. R., Del Castillo, T. J., Czerwinski, D. K., Rajapaksa, R., … Levy, R. (2022). Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. Biomacromolecules.

PARP14 is a novel target in STAT6 mutant follicular lymphoma.
Mentz, M., Keay, W., Strobl, C. D., Antoniolli, M., Adolph, L., Heide, M., … Weigert, O. (2022). PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia.

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., … Levy, R. (2021). Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions
Haebe, S., Shree, T., Day, G., Sathe, A., Czerwinski, D. K., Grimes, S. M., … Levy, R. (2021). In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions. BLOOD. AMER SOC HEMATOLOGY.

Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation
Shree, T., Haebe, S., Czerwinski, D. K., Day, G., Sathe, A., Khodadoust, M. S., … Levy, R. (2021). Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. BLOOD. AMER SOC HEMATOLOGY.

In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity
Barfi, I. S., Czerwinski, D. K., & Levy, R. (2021). In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity. BLOOD. AMER SOC HEMATOLOGY.

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2022). Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program
McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., … Dallaire, B. K. (2023). Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. JOURNAL OF CLINICAL ONCOLOGY, 41(2), 154–162.

Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma
Haebe, S., Shree, T., Day, G., Czerwinski, D. K., Sathe, A., Grimes, S. M., … Levy, R. (2022). Prevalence of Acquired N-Glycosylation Sites at the Single Cell Level in Follicular Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs.
Blake, T. R., Haabeth, O. A., Sallets, A., McClellan, R. L., Del Castillo, T. J., Vilches-Moure, J. G., … Waymouth, R. M. (2023). Lysine-Derived Charge-Altering Releasable Transporters: Targeted Delivery of mRNA and siRNA to the Lungs. Bioconjugate Chemistry.

PROFILING THE EFFECTS OF TARGETED TLR9 STIMULATION WITHIN SPONTANEOUSLY ARISING BREAST TUMORS
Miller, C., Sagiv-Barfi, I., Neuhoefer, P., Czerwinski, D., Bertozzi, C., Cochran, J., & Levy, R. (2022). PROFILING THE EFFECTS OF TARGETED TLR9 STIMULATION WITHIN SPONTANEOUSLY ARISING BREAST TUMORS. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.

Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors.
Miller, C. L., Sagiv-Barfi, I., Neuhöfer, P., Czerwinski, D. K., Bertozzi, C. R., Cochran, J. R., & Levy, R. (2023). Targeted TLR9 Agonist Elicits Effective Antitumor Immunity against Spontaneously Arising Breast Tumors. Journal of Immunology (Baltimore, Md. : 1950).

The molecular mechanism of CD81 antibody inhibition of metastasis.
Abu-Saleh, N., Kuo, C.-C. C., Jiang, W., Levy, R., & Levy, S. (2023). The molecular mechanism of CD81 antibody inhibition of metastasis. Proceedings of the National Academy of Sciences of the United States of America, 120(26), e2305042120.

Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer.
Grimes, S. M., Kim, H. S., Roy, S., Sathe, A., Ayala, C. I., Bai, X., … Ji, H. P. (2023). Single-cell multi-gene identification of somatic mutations and gene rearrangements in cancer. NAR Cancer, 5(3), zcad034.

Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor.
Haebe, S. E., Day, G., Czerwinski, D. K., Sathe, A., Grimes, S. M., Chen, T., … Levy, R. (2023). Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor. Blood.

A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.
Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., … Levy, R. (2023). A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis. Blood Advances.

Co-Occurrence of Clonally Related Follicular Lymphoma and Histiocytic Sarcoma
Haebe, S., Czerwinski, D. K., Sathe, A., Grimes, S., Chen, T., Martin, B., … Shree, T. (2023). Co-Occurrence of Clonally Related Follicular Lymphoma and Histiocytic Sarcoma. BLOOD. AMER SOC HEMATOLOGY.

Loss of the OX40 Target in Lymphoma Patients after Combining an Anti-OX40 Agonist Antibody with in Situ Vaccination
Czerwinski, D. K., Shree, T., Haebe, S., Shi, S., Long, S. R., Martin, B., & Levy, R. (2023). Loss of the OX40 Target in Lymphoma Patients after Combining an Anti-OX40 Agonist Antibody with in Situ Vaccination. BLOOD. AMER SOC HEMATOLOGY.

Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma
Kirane, A., Lee, D., Ahmad, M. U., Sharma, S., Serasanambati, M., Lowe, M., … Maverakis, E. (2024). Toward the Development of Functional Biomarker Assays: Analysis of Neoadjuvant Intralesional Oncolytic Virus Response in High-Risk Stage II Melanoma. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.

Isoprenoid CARTs: In Vitro and In Vivo mRNA Delivery by Charge-Altering Releasable Transporters Functionalized with Archaea-inspired Branched Lipids.
Rahn, H. P., Sun, J., Li, Z., Waymouth, R. M., Levy, R., & Wender, P. A. (2024). Isoprenoid CARTs: In Vitro and In Vivo mRNA Delivery by Charge-Altering Releasable Transporters Functionalized with Archaea-inspired Branched Lipids. Biomacromolecules.